<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07-PONE-RA-02303R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0001372</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Molecular Biology</subject><subject>Cell Biology/Cell Signaling</subject><subject>Cell Biology/Cellular Death and Stress Responses</subject><subject>Gastroenterology and Hepatology/Hepatology</subject></subj-group></article-categories><title-group><article-title>A Ribosomal S-6 Kinase&#x02013;Mediated Signal to C/EBP-&#x003b2; Is Critical for the Development of Liver Fibrosis</article-title><alt-title alt-title-type="running-head">RSK and Liver Fibrosis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Buck</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chojkier</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Medicine and Moores Cancer Center, University of California at San Diego, La Jolla, California, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Medicine, Veterans Affairs (VA) Healthcare Center, San Diego, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Cordes</surname><given-names>Nils</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Dresden University of Technology, Germany</aff><author-notes><corresp id="cor1">&#x0002a; To whom correspondence should be addressed. E-mail: <email>mbuck@ucsd.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: MC MB. Performed the experiments: MB. Analyzed the data: MC MB. Wrote the paper: MC MB.</p></fn></author-notes><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>26</day><month>12</month><year>2007</year></pub-date><volume>2</volume><issue>12</issue><elocation-id>e1372</elocation-id><history><date date-type="received"><day>20</day><month>9</month><year>2007</year></date><date date-type="accepted"><day>3</day><month>12</month><year>2007</year></date></history><copyright-statement>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</copyright-statement><copyright-year>2007</copyright-year><abstract><sec><title>Background</title><p>In response to liver injury, hepatic stellate cell (HSC) activation causes excessive liver fibrosis. Here we show that activation of RSK and phosphorylation of C/EBP&#x003b2; on Thr217 in activated HSC is critical for the progression of liver fibrosis.</p></sec><sec><title>Methodology/Principal Findings</title><p>Chronic treatment with the hepatotoxin CCl<sub>4</sub> induced severe liver fibrosis in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice but not in mice expressing C/EBP&#x003b2;-Ala217, a non-phosphorylatable RSK-inhibitory transgene. C/EBP&#x003b2;-Ala217 was present within the death receptor complex II, with active caspase 8, and induced apoptosis of activated HSC. The C/EBP&#x003b2;-Ala217 peptides directly stimulated caspase 8 activation in a cell-free system. C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice with CCl<sub>4</sub>-induced severe liver fibrosis, while continuing on CCl<sub>4</sub>, were treated with a cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The peptide inhibited RSK activation, stimulating apoptosis of HSC, preventing progression and inducing regression of liver fibrosis. We found a similar activation of RSK and phosphorylation of human C/EBP&#x003b2; on Thr266 (human phosphoacceptor) in activated HSC in patients with severe liver fibrosis but not in normal livers, suggesting that this pathway may also be relevant in human liver fibrosis.</p></sec><sec><title>Conclusions/Significance</title><p>These data indicate that the RSK-C/EBP&#x003b2; phosphorylation pathway is critical for the development of liver fibrosis and suggest a potential therapeutic target.</p></sec></abstract><counts><page-count count="15"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The annual worldwide mortality from liver cirrhosis is approximately 800,000 <xref ref-type="bibr" rid="pone.0001372-1">&#x0005b;1&#x0005d;</xref>, and there is no available treatment <xref ref-type="bibr" rid="pone.0001372-2">&#x0005b;2&#x0005d;</xref>. Excessive tissue repair in chronic liver diseases induced by viral, toxic, immunologic, and metabolic disorders <xref ref-type="bibr" rid="pone.0001372-Chung1">&#x0005b;3&#x0005d;</xref>, results in the deposition of scar tissue and the development of cirrhosis <xref ref-type="bibr" rid="pone.0001372-Chojkier1">&#x0005b;4&#x0005d;</xref>. Quiescent hepatic stellate cells (HSC) produce negligible amounts of extracellular matrix proteins (ECM), but after their activation, these cells develop a myofibroblastic phenotype, proliferate and become the main contributors of ECM <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Lee1">&#x0005b;6&#x0005d;</xref>. This step is required for the development of liver fibrosis and cirrhosis <xref ref-type="bibr" rid="pone.0001372-Friedman1">&#x0005b;7&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001372-AnkomaSey1">&#x0005b;9&#x0005d;</xref>.</p><p>The mitogen-activated protein kinase (MAPK) pathway, through the extracellular signal-regulated kinase (ERK1/2), activates RSK <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001372-SassoneCorsi1">&#x0005b;14&#x0005d;</xref>, resulting in the phosphorylation of mouse C/EBP&#x003b2; (NP_034013 XP_916631) on Thr217 (Thr266 in human C/EBP&#x003b2;) <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>. The RSK pathway may be critical for HSC activation induced by liver injury, because expression of a catalytically inactive mutant RSK <xref ref-type="bibr" rid="pone.0001372-Nakajima1">&#x0005b;15&#x0005d;</xref>, blocked proliferation and survival of cultured HSC upon their activation by collagen type 1 <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>. The RSK phosphoacceptor site in C/EBP&#x003b2; is identical in mouse and human, it is evolutionarily conserved <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref>, and essential for survival of activated HSC <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>.</p><p>Here we show that activation of RSK and phosphorylation of C/EBP&#x003b2; on Thr217 in activated HSC is critical for the progression of liver fibrosis. Chronic exposure to the hepatotoxin CCl<sub>4</sub> can induce liver cirrhosis in humans, and it is a classical method of inducing liver injury and fibrosis in mice <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Rudolph1">&#x0005b;16&#x0005d;</xref>. We used this model to investigate the role of RSK and phosphorylation of C/EBP&#x003b2; on Thr217 in liver fibrosis. The hepatotoxin CCl<sub>4</sub> induced severe liver fibrosis in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice but not in mice expressing C/EBP&#x003b2;-Ala217, a non-phosphorylatable RSK-inhibitory transgene. C/EBP&#x003b2;-Ala217 was present within the death receptor complex II, with active caspase 8, and induced apoptosis of activated HSC. C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice with severe liver fibrosis induced by an 8-week CCl<sub>4 </sub>treatment, while continuing on CCl<sub>4</sub>, were treated with a cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The peptide inhibited RSK activation, stimulating apoptosis of HSC, preventing progression and inducing regression of liver fibrosis compared to control mice treated with CCl<sub>4</sub>. We found similar activation of RSK and phosphorylation of human C/EBP&#x003b2; (NP_005185) on Thr266 (identical human phosphoacceptor) in activated HSC in the liver of patients with severe liver fibrosis. These data indicate that the RSK-C/EBP&#x003b2; phosphorylation pathway is critical for the development of liver fibrosis, and that inhibition of the RSK pathway is a potential therapeutic strategy for the prevention and treatment of liver cirrhosis.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Mice expressing the RSK-inhibitory C/EBP&#x003b2;-Ala217 transgene are resistant to hepatotoxin-induced liver fibrosis</title><p>Given the important role of RSK in the activation of HSC <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>, we hypothesized that a RSK-inhibitory transgenic protein would block phosphorylation of C/EBP&#x003b2; on Thr217, induce HSC apoptosis and decrease liver fibrosis following chronic liver injury. Because the chronic exposure to the hepatotoxin CCl<sub>4</sub> can induce liver cirrhosis in humans, and it is a classical method of inducing liver injury and fibrosis in mice <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Rudolph1">&#x0005b;16&#x0005d;</xref>, we analyzed whether it induces liver cirrhosis in mice expressing the dominant negative, nonphosphorylatable RSK-inhibitory C/EBP&#x003b2;-Ala217 transgene. This mutation changes the phosphorylatable Thr217 to a nonphosphorylatable Ala217 within the RSK phosphoacceptor site of C/EBP&#x003b2;. These animals are developmentally normal, fertile and have a normal life span <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>, suggesting that the RSK-inhibitory transgene is apparently not toxic.</p><p>After the thrice-weekly intraperitoneal administration of CCl<sub>4 </sub>for 12 weeks, we determined the degree of liver fibrosis in coded samples. This is an extensive chronic exposure for mice and comparable to established severe liver fibrosis in humans <xref ref-type="bibr" rid="pone.0001372-Constandinou1">&#x0005b;17&#x0005d;</xref>. We evaluated liver fibrosis employing the following methods: i) microscopic morphology; ii) semi-quantitative METAVIR clinical grading system; iii) collagen type 1 immunofluorescence; iv) quantitative Sirius red collagen-binding assay; v) quantitative hydroxyproline collagen content; vi) RT-PCR for collagen type 1 mRNA; vii) RT-PCR for &#x003b1;-smooth muscle actin (&#x003b1;-SMA) mRNA (present in activated HSC); and viii) RT-PCR for transforming growth factor (TGF-&#x003b2;) mRNA (a pro-fibrotic cytokine) <xref ref-type="bibr" rid="pone.0001372-Chojkier1">&#x0005b;4&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Friedman1">&#x0005b;7&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Bataller1">&#x0005b;8&#x0005d;</xref>.</p><p>Liver samples were stained with the classical Mallory's trichrome to identify collagen in the extracellular matrix. The hepatic collagen pattern and content of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> (wt) mice treated with CCl<sub>4</sub> for 12 weeks were similar to those of patients with liver cirrhosis (<xref ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1A</underline></xref>) <xref ref-type="bibr" rid="pone.0001372-Chojkier1">&#x0005b;4&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Bataller1">&#x0005b;8&#x0005d;</xref>. We graded the coded liver samples with the standard 0 to 4 METAVIR clinical system <xref ref-type="bibr" rid="pone.0001372-Bedossa1">&#x0005b;18&#x0005d;</xref>, and found that after CCl<sub>4 </sub>treatment, all C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice had severe liver fibrosis (grade 4; <italic>n</italic>: 12), while all C/EBP&#x003b2;-Ala217 mice had minimal or no liver fibrosis (grade 0; <italic>n</italic>: 6; grade 1; <italic>n</italic>: 6) (<italic>P</italic>&#x0003c;0.0001) (<xref ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1A</underline></xref>). In agreement with the findings with the Mallory's trichrome, the Sirius red collagen-binding stain also demonstrated decreased liver fibrosis after CCl<sub>4 </sub>treatment in C/EBP&#x003b2;-Ala217 mice (<xref ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1B</underline></xref>). Similarly, confocal scanning microscopy with specific antibodies against collagen type 1 also identify decreased liver fibrosis in C/EBP&#x003b2;-Ala217 mice, compared to C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice, after CCl<sub>4 </sub>treatment (<xref ref-type="supplementary-material" rid="pone.0001372.s002"><underline>Figure S1</underline></xref>). Although the intra- and inter-observer variability in the semi-quantitative analysis of liver fibrosis was low, we confirmed these findings using quantitative analysis of liver fibrosis.</p><fig id="pone-0001372-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001372.g001</object-id><label>Figure 1</label><caption><title>Mice expressing the RSK-inhibitory C/EBP&#x003b2;-Ala217 transgene are refractory to the induction of liver fibrosis.</title><p>C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> &#x0005b;wt&#x0005d;, C/EBP&#x003b2;-Ala217 and C/EBP&#x003b2;<sup>&#x02212;/&#x02212; </sup>&#x0005b;ko&#x0005d; mice received weekly IP injections of CCl<sub>4</sub> or mineral oil (control) for 12 weeks as described in <xref ref-type="sec" rid="s4">Methods</xref>. A. Representative Mallory's trichrome stain for liver fibrosis (in blue; arrowheads). All C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> (wt) mice (<italic>n</italic>: 12) developed severe liver fibrosis. The C/EBP&#x003b2;-Ala217 (<italic>n</italic>: 12; <italic>P&#x0003c;0.0001</italic>) and C/EBP&#x003b2;<sup>&#x02212;/&#x02212; </sup>&#x0005b;ko&#x0005d; (<italic>n</italic>: 6; <italic>P&#x0003c;0.01</italic>) mice had either no fibrosis or only minimal liver fibrosis. B. Representative Sirius red immunohistochemistry for collagen (in red; arrowhead). Marked increase in liver collagen in a cirrhotic pattern was observed in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup>, but not in C/EBP&#x003b2;-Ala 217 or C/EBP&#x003b2;<sup>&#x02212;/&#x02212;</sup> &#x0005b;ko&#x0005d;, mice. C. Analysis of hepatic collagen content by the Sirius red collagen&#x02013;binding assay, showed a &#x0223c;2.5-fold increase in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice treated with CCl<sub>4</sub> (<italic>n</italic>: 12), compared to C/EBP&#x003b2;-Ala217 mice treated with CCl<sub>4</sub> (<italic>n</italic>: 12; <italic>P&#x0003c;0.001</italic>). C/EBP&#x003b2;<sup>&#x02212;/&#x02212;</sup> mice were also refractory to the induction of liver fibrosis by CCl<sub>4</sub> (<italic>n</italic>: 6; <italic>P&#x0003c;0.01</italic>). D. Analysis of hepatic collagen content by the hydroxyproline assay, showed a &#x0223c;2-fold increase in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice treated with CCl<sub>4</sub> (<italic>n</italic>: 7), compared to C/EBP&#x003b2;-Ala217 mice treated with CCl<sub>4</sub> (<italic>n</italic>: 6; <italic>P&#x0003c;0.01</italic>). C/EBP&#x003b2;<sup>&#x02212;/&#x02212;</sup> mice were also refractory to the induction of liver fibrosis by CCl<sub>4</sub> (<italic>n</italic>: 6; <italic>P&#x0003c;0.01</italic>).</p></caption><graphic xlink:href="pone.0001372.g001"/></fig><p>The quantitative analysis of liver collagen, the major extracellular matrix protein in liver fibrosis <xref ref-type="bibr" rid="pone.0001372-Chojkier1">&#x0005b;4&#x0005d;</xref>, with the Sirius red collagen-binding assay <xref ref-type="bibr" rid="pone.0001372-Jimenez1">&#x0005b;19&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1C</underline></xref>), demonstrated that C/EBP&#x003b2;-Ala217 mice were refractory to the development of liver fibrosis after chronic exposure to the hepatotoxin. The liver collagen content increased approximately 2.5-fold from baseline in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> (wt) mice (<italic>P</italic>&#x0003c;0.001) while remaining unchanged in C/EBP&#x003b2;-Ala217 mice (NS) (<xref ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1C</underline></xref>). Similarly, chronic administration of CCl<sub>4</sub> increased liver hydroxyproline collagen content in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> (wt) mice (<italic>P</italic>&#x0003c;0.01) while remaining unchanged in C/EBP&#x003b2;-Ala217 mice (NS) (<xref ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1D</underline></xref>).</p><p>We have reported that by lacking the essential C/EBP&#x003b2;-PhosphoThr217, C/EBP&#x003b2;&#x02212;/&#x02212; HSC are also unable to survive the activation signals <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>. Thus, we postulated that C/EBP&#x003b2;&#x02212;/&#x02212; mice would be refractory to the induction of liver fibrosis. Indeed, C/EBP&#x003b2;<sup>&#x02212;/&#x02212; </sup>(ko) mice had a lower fibrotic response than C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice to the chronic treatment with CCl<sub>4</sub> (<italic>P</italic>&#x0003c;0.01) (<xref ref-type="fig" rid="pone-0001372-g001"><underline>Figure 1</underline></xref><underline>A, B, C and D</underline>).</p><p>Further, the expression of the liver fibrogenic indicators such as collagen &#x003b1; 1 type 1 mRNA (newly synthesized collagen) (NM_007742 )(<italic>P&#x0003c;0.01</italic>), &#x003b1;-SMA mRNA (activated HSC) (NM_007392.2) (<italic>P&#x0003c;0.05</italic>), and TGF-&#x003b2; mRNA (fibrogenic cytokine) (NM_009370.2) (<italic>P&#x0003c;0.01</italic>), were induced by CCl<sub>4 </sub>treatment significantly more in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice than in C/EBP&#x003b2;-Ala217 mice as measured by RT-PCR (<xref ref-type="fig" rid="pone-0001372-g002"><underline>Figure 2</underline></xref>).</p><fig id="pone-0001372-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001372.g002</object-id><label>Figure 2</label><caption><title>Mice expressing the RSK-inhibitory C/EBP&#x003b2;-Ala217 transgene are resistant to hepatotoxin-induced liver fibrogenesis.</title><p>Mice were treated with CCl<sub>4</sub> or control mineral oil for 12 or 16 weeks and RT-PCR was performed as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref>. A. RT-PCR for collagen &#x003b1;1 type 1 was induced in C/EBP&#x003b2; <sup>&#x0002b;/&#x0002b;</sup> &#x0005b;wt&#x0005d; mice treated with CCl<sub>4</sub> for 12 or 16 weeks (<italic>P&#x0003c;0.01</italic>). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref> blocked this increase at week 16 (<italic>P&#x0003c;0.05</italic>). Collagen &#x003b1;1 type 1 was not increased in livers of C/EBP&#x003b2;-Ala217 mice at 12 or 16 weeks (<italic>P&#x0003c;0.01</italic>). B. RT-PCR for &#x003b1;-SMA was induced in C/EBP&#x003b2; <sup>&#x0002b;/&#x0002b; </sup>&#x0005b;wt&#x0005d; mice treated with CCl<sub>4 </sub>for 12 or 16 weeks (<italic>P&#x0003c;0.05</italic>). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref> blocked this increase at week 16 (<italic>P&#x0003c;0.05</italic>). &#x003b1;-SMA was not increased in livers of C/EBP&#x003b2;-Ala217 mice at 12 or 16 weeks (<italic>P&#x0003c;0.05</italic>). C. RT-PCR for TGF-&#x003b2; was induced in C/EBP&#x003b2; <sup>&#x0002b;/&#x0002b; </sup>&#x0005b;wt&#x0005d; mice treated with CCl<sub>4 </sub>for 12 or 16 weeks (<italic>P&#x0003c;0.01</italic>). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref>, blocked this increase at week 16 (<italic>P&#x0003c;0.01</italic>). TGF-&#x003b2; was not increased in livers of C/EBP&#x003b2;-Ala217 mice at 12 or 16 weeks (<italic>P&#x0003c;0.01</italic>).</p></caption><graphic xlink:href="pone.0001372.g002"/></fig><p>In summary, blocking phosphorylation of C/EBP&#x003b2;-Thr217 through the inhibition of RSK activity with the C/EBP&#x003b2;-Ala217 transgene or by C/EBP&#x003b2; gene knock-out decreases the fibrotic response of the liver to chronic injury.</p></sec><sec id="s2b"><title>Mice expressing the RSK-inhibitory C/EBP&#x003b2;-Ala217 transgene are resistant to hepatotoxin-induced liver inflammation</title><p>Because liver inflammation, at least in part through the activation of macrophages <xref ref-type="bibr" rid="pone.0001372-Chojkier2">&#x0005b;20&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001372-Matsuoka1">&#x0005b;22&#x0005d;</xref> and loss of hepato-trophic factors from HSC and liver endothelial cells <xref ref-type="bibr" rid="pone.0001372-Passino1">&#x0005b;23&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-LeCouter1">&#x0005b;24&#x0005d;</xref> is a major contributor to liver injury and liver fibrosis, we assessed the degree of liver injury and inflammation in response to the hepatotoxin. Liver injury was determined by measuring serum alanine aminotransferase (ALT) levels in mice after exposure to the hepatotoxin. Serum ALT is a sensitive and specific indicator of hepatocellular injury in humans and animals, and it is the standard clinical test used by the U.S. Food and Drug Administration to ascertain hepatotoxicity of herbal products and drugs <xref ref-type="bibr" rid="pone.0001372-Chojkier3">&#x0005b;25&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Chojkier4">&#x0005b;26&#x0005d;</xref>. We found that C/EBP&#x003b2;-Ala217 mice had less liver injury than C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice after CCl<sub>4</sub> treatment, judging by the ALT serum levels (<xref ref-type="supplementary-material" rid="pone.0001372.s001"><underline>Table S1</underline></xref>).</p><p>Using a microarray assay to assess expression of 66 inflammation genes in the liver of control and transgenic mice, we found that the expression of 21 inflammation genes was decreased, while the expression of other 45 inflammation genes was unchanged in C/EBP&#x003b2;-Ala217 mice after CCl<sub>4</sub>&#x02013;induced liver injury, when compared to C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> animals treated with CCl<sub>4</sub> (<xref ref-type="table" rid="pone-0001372-t001"><underline>Table 1</underline></xref>).</p><table-wrap id="pone-0001372-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001372.t001</object-id><label>Table 1</label><caption><title>Decreased Inflammation in the Livers of C/EBP&#x003b2;- Ala217 mice after CCl<sub>4</sub> treatment.</title></caption><graphic id="pone-0001372-t001-1" xlink:href="pone.0001372.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001372-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">#</td><td align="left" rowspan="1" colspan="1">GeneBank</td><td align="left" rowspan="1" colspan="1">Symbol</td><td align="left" rowspan="1" colspan="1">Description</td><td align="left" rowspan="1" colspan="1">Gene Name</td><td align="left" rowspan="1" colspan="1">Liver Expression in C/EBP&#x003b2;- A 217 (&#x00025; of control)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">NM_009744</td><td align="left" rowspan="1" colspan="1">Bcl6</td><td align="left" rowspan="1" colspan="1">B-cell leukemia/lymphoma 6</td><td align="left" rowspan="1" colspan="1">Bcl5</td><td align="left" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">NM_009807</td><td align="left" rowspan="1" colspan="1">Casp1</td><td align="left" rowspan="1" colspan="1">Caspase 1</td><td align="left" rowspan="1" colspan="1">ICE/IL 1bc</td><td align="left" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">NM_011331</td><td align="left" rowspan="1" colspan="1">Ccl12</td><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 12</td><td align="left" rowspan="1" colspan="1">MCP-5/Scya12</td><td align="left" rowspan="1" colspan="1">32</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">NM_011888</td><td align="left" rowspan="1" colspan="1">Ccl19</td><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 19</td><td align="left" rowspan="1" colspan="1">CKb11/ELC</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">NM_021443</td><td align="left" rowspan="1" colspan="1">Ccl8</td><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 8</td><td align="left" rowspan="1" colspan="1">1810063B20Rik/AB023418</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">NM_011338</td><td align="left" rowspan="1" colspan="1">Ccl9</td><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 9</td><td align="left" rowspan="1" colspan="1">CCF18/MRP-2</td><td align="left" rowspan="1" colspan="1">27</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">NM_009915</td><td align="left" rowspan="1" colspan="1">Ccr2</td><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) receptor 2</td><td align="left" rowspan="1" colspan="1">CC-CKR-2/CCR2A</td><td align="left" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">NM_009916</td><td align="left" rowspan="1" colspan="1">Ccr4</td><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) receptor 4</td><td align="left" rowspan="1" colspan="1">Cmkbr4/LESTR</td><td align="left" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">NM_009142</td><td align="left" rowspan="1" colspan="1">Cx3cl1</td><td align="left" rowspan="1" colspan="1">Chemokine (C-X3-C motif) ligand 1</td><td align="left" rowspan="1" colspan="1">AB030188/ABCD-3</td><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">NM_021704</td><td align="left" rowspan="1" colspan="1">Cxcl12</td><td align="left" rowspan="1" colspan="1">Chemokine (C-X-C motif) ligand 12</td><td align="left" rowspan="1" colspan="1">AI174028/PBSF</td><td align="left" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">NM_009141</td><td align="left" rowspan="1" colspan="1">Cxcl5</td><td align="left" rowspan="1" colspan="1">Chemokine (C-X-C motif) ligand 5</td><td align="left" rowspan="1" colspan="1">AMCF-II/ENA-78</td><td align="left" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">NM_008599</td><td align="left" rowspan="1" colspan="1">Cxcl9</td><td align="left" rowspan="1" colspan="1">Chemokine (C-X-C motif) ligand 9</td><td align="left" rowspan="1" colspan="1">BB139920/CMK</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">NM_010548</td><td align="left" rowspan="1" colspan="1">IL10</td><td align="left" rowspan="1" colspan="1">Interleukin 10</td><td align="left" rowspan="1" colspan="1">CSIF/IL-10</td><td align="left" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">NM_008349</td><td align="left" rowspan="1" colspan="1">IL10rb</td><td align="left" rowspan="1" colspan="1">Interleukin 10 receptor, beta</td><td align="left" rowspan="1" colspan="1">6620401D04Rik/AI528744</td><td align="left" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">NM_010551</td><td align="left" rowspan="1" colspan="1">IL16</td><td align="left" rowspan="1" colspan="1">Interleukin 16</td><td align="left" rowspan="1" colspan="1">mKIAA4048</td><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">NM_008360</td><td align="left" rowspan="1" colspan="1">IL18</td><td align="left" rowspan="1" colspan="1">Interleukin 18</td><td align="left" rowspan="1" colspan="1">Igif/IL-18</td><td align="left" rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">NM_010555</td><td align="left" rowspan="1" colspan="1">Il1r2</td><td align="left" rowspan="1" colspan="1">Interleukin 1 receptor, type II</td><td align="left" rowspan="1" colspan="1">CD121b/IL1r-2</td><td align="left" rowspan="1" colspan="1">27</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">NM_008368</td><td align="left" rowspan="1" colspan="1">IL2rb</td><td align="left" rowspan="1" colspan="1">Interleukin 2 receptor, beta chain</td><td align="left" rowspan="1" colspan="1">CD122/IL-15Rbeta</td><td align="left" rowspan="1" colspan="1">32</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">NM_013563</td><td align="left" rowspan="1" colspan="1">IL2rg</td><td align="left" rowspan="1" colspan="1">Interleukin 2 receptor, gamma chain</td><td align="left" rowspan="1" colspan="1">CD132/&#x0005b;g&#x0005d;c</td><td align="left" rowspan="1" colspan="1">32</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">NM_009263</td><td align="left" rowspan="1" colspan="1">Spp1</td><td align="left" rowspan="1" colspan="1">Secreted phosphoprotein 1</td><td align="left" rowspan="1" colspan="1">AA960535/AI790405</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">NM_011798</td><td align="left" rowspan="1" colspan="1">Xcr1</td><td align="left" rowspan="1" colspan="1">Chemokine (C motif) receptor 1</td><td align="left" rowspan="1" colspan="1">Ccxcr1/GPR5</td><td align="left" rowspan="1" colspan="1">17</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>Animals received either mineral oil &#x0005b;MO&#x0005d; or CCl<sub>4</sub>. Thirty hours after a single intraperitoneal dose of CCl<sub>4</sub>,</p></fn><fn id="nt102"><p>C/EBP&#x003b2; Ala217 (<italic>n</italic>: 9) mice had a markedly decreased liver expression of inflammatory genes compared to C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice (<italic>n</italic>: 9). A panel of 86 inflammatory genes were evaluated by RT-QPCR; 21 of these genes were significantly reduced (P&#x0003c;0.05 for all 21 genes).</p></fn></table-wrap-foot></table-wrap><p>These data suggest that partial resistance to liver injury and inflammation may contribute to the prevention of liver fibrosis in C/EBP&#x003b2;-Ala217 mice. A decreased inflammatory response, mediated at least in part by monocytes/macrophages in the livers of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice (<xref ref-type="fig" rid="pone-0001372-g003"><underline>Figure 3A</underline></xref>), may be responsible for the decreased liver injury in C/EBP&#x003b2;-Ala217 mice, since RSK inhibition also affected the recruitment of CD-68&#x0002b; inflammatory cells to the liver (<xref ref-type="fig" rid="pone-0001372-g003"><underline>Figure 3B</underline></xref>).</p><fig id="pone-0001372-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001372.g003</object-id><label>Figure 3</label><caption><title>Mice expressing the RSK-inhibitory C/EBP&#x003b2;-Ala217 transgene are resistant to hepatotoxin-induced liver inflammation.</title><p>Mice were treated with CCl<sub>4</sub> or control mineral oil for 16 weeks as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref>. A. Activated monocytes/macrophages, identified by confocal microscopy for CD-68 (green), were increased in livers of C/EBP&#x003b2; <sup>&#x0002b;/&#x0002b;</sup> &#x0005b;wt&#x0005d; mice treated with CCl<sub>4</sub> for 16 weeks (middle panels). Treatment of these animals after week 8 with the RSK-inhibitory peptide while continuing the exposure to the hepatotoxin, as described in <xref ref-type="sec" rid="s4">Material and methods</xref>, blocked the monocytes/macrophage inflammatory reaction at week 16 (lower panels). Nuclei are identified with TO-PRO-3 (blue). Only background staining was observed when omitting the first antibody. Microscopy shown is representative of six animals in each group. B. Activated monocytes/macrophages, were not increased in livers of C/EBP&#x003b2;-Ala217 mice as much as in the livers of C/EBP&#x003b2; <sup>&#x0002b;/&#x0002b;</sup> &#x0005b;wt&#x0005d; mice after treatment with CCl<sub>4</sub> for 16 weeks (lower panel). Microscopy shown is representative of six animals in each group.</p></caption><graphic xlink:href="pone.0001372.g003"/></fig><p>Given that CCl<sub>4</sub> is metabolized by the cythocrome-P-450 2E-1(Cyp-2E-1) (ABH07947) to form a free radical hepatotoxic metabolite <xref ref-type="bibr" rid="pone.0001372-Koop1">&#x0005b;27&#x0005d;</xref>, we evaluated the possibility that C/EBP&#x003b2;-Ala217 affects Cyp-2E1 expression and/or activity. The Cyp-2E1 mRNA expression was similarly inhibited by CCl<sub>4</sub> in the livers of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> and C/EBP&#x003b2;-Ala217 mice (<xref ref-type="supplementary-material" rid="pone.0001372.s003"><underline>Figure S2A</underline></xref>). In addition, the Cyp-2E-1 protein expression was also similar in the livers of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> and C/EBP&#x003b2;-Ala217 mice after the hepatotoxin treatment (<xref ref-type="supplementary-material" rid="pone.0001372.s003"><underline>Figure S2B</underline></xref>). Moreover, the Cyp-2E1 activity as measured in a cell-free system was unaltered by a RSK-inhibitory C/EBP&#x003b2;-Ala217 peptide, even at &#x000b5;M concentrations (<xref ref-type="supplementary-material" rid="pone.0001372.s003"><underline>Figure S2C</underline></xref>).</p><p>These results indicate that the protective effects of the RSK-inhibitory transgene in CCl<sub>4</sub> -induced liver injury and fibrosis are not due to the spurious blockade of the production of a toxic CCl<sub>4</sub> metabolite.</p></sec><sec id="s2c"><title>Mice expressing the RSK-inhibitory C/EBP&#x003b2;-Ala217 transgene are resistant to hepatotoxin-induced HSC activation and proliferation</title><p>Quiescent HSC produce negligible amounts of ECM, but after their activation, these cells develop a myofibroblastic phenotype, proliferate, and become the main contributors of ECM <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Lee1">&#x0005b;6&#x0005d;</xref>. Because this step is required for the development of liver fibrosis and cirrhosis <xref ref-type="bibr" rid="pone.0001372-Friedman1">&#x0005b;7&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001372-AnkomaSey1">&#x0005b;9&#x0005d;</xref>, we analyzed the activation and proliferation of HSC in the livers of mice chronically exposed to the hepatotoxin.</p><p>As expected, chronic CCl<sub>4</sub> administration to C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> (wt) mice, induced marked activation of HSC, as indicated by the positive immunofluorescence for &#x003b1;-SMA within the scar tissue <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Lee1">&#x0005b;6&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0001372-g004"><underline>Figure 4A</underline></xref>), and proliferation of HSC, as indicated by the presence of proliferating cell nuclear antigen (PCNA; DNA polymerase &#x003b4; auxiliary protein), an S-phase marker <xref ref-type="bibr" rid="pone.0001372-Bravo1">&#x0005b;28&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0001372-g004"><underline>Figure 4B</underline></xref>). By contrast, C/EBP&#x003b2;-Ala217 mice were refractory to the induction of HSC activation and proliferation by CCl<sub>4</sub> treatment (<xref ref-type="fig" rid="pone-0001372-g004"><underline>Figure 4A and B</underline></xref>). Moreover, chronic CCl<sub>4</sub> treatment induced the apoptotic cascade in HSC in the livers of C/EBP&#x003b2;-Ala217 mice, but not C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice, as determined by the presence of active caspase 3 immunofluorescence (<xref ref-type="fig" rid="pone-0001372-g004"><underline>Figure 4B</underline></xref>). After chronic CCl<sub>4</sub> administration, C/EBP&#x003b2; was phosphorylated on Thr217 in HSC of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice, but not in C/EBP&#x003b2;-Ala217 mice, as determined by confocal microscopy (<xref ref-type="fig" rid="pone-0001372-g004"><underline>Figure 4A and B</underline></xref>), using specific antibodies against this phosphorylated epitope <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;<underline>10</underline>&#x0005d;</xref>.</p><fig id="pone-0001372-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001372.g004</object-id><label>Figure 4</label><caption><title>Mice expressing the RSK-inhibitory C/EBP&#x003b2;-Ala217 transgene are refractory to hepatic stellate cell activation and proliferation.</title><p>Mice received CCl<sub>4 </sub>or mineral oil injections for 12 weeks as described in <xref ref-type="sec" rid="s4">Materials and methods</xref>. A. Activated stellate cells, identified by confocal microscopy for &#x003b1;-smooth muscle actin (&#x003b1;-SMA; red), displayed C/EBP&#x003b2;-PhosphoThr217 (green) in livers of C/EBP&#x003b2; <sup>&#x0002b;/&#x0002b;</sup> &#x0005b;wt&#x0005d;, but not C/EBP&#x003b2;-Ala217, mice treated with CCl<sub>4</sub>. Colocalization of &#x003b1;-SMA and C/EBP&#x003b2;-PhosphoThr217 is shown in yellow (merge). Nuclei are identified with TO-PRO-3 (blue). Only background staining was observed when omitting the first antibody. B. Proliferating cell nuclear antigen (PCNA; red) was present in activated stellate cells only in livers of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> &#x0005b;wt&#x0005d; mice treated with CCl<sub>4</sub>, while active caspase 3 (green) was found in HSC only in livers of C/EBP&#x003b2;-Ala217 mice treated with CCl<sub>4</sub>. Nuclei are identified with TO-PRO-3 (blue).</p></caption><graphic xlink:href="pone.0001372.g004"/></fig><p>Because the mixed cell population of the liver limits the evaluation of signaling cascades in a specific cell type, we studied the fibrogenic pathway in purified HSC. After chronic CCl<sub>4</sub> or control mineral oil administration, we analyzed proteins associated with C/EBP&#x003b2;, immunopurified from HSC, freshly isolated from C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> and C/EBP&#x003b2;-Ala217 mice. C/EBP&#x003b2;-Ala217 binding to, and blocking, RSK phosphorylation (<xref ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5A</underline></xref>) results in decreased phosphorylation of C/EBP&#x003b2; on Thr217, and presumably, other target survival proteins by activated RSK <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Bonni1">&#x0005b;11&#x0005d;</xref>. The Ac-KAla217VD-CHO or C/EBP&#x003b2;216-253-Ala217 (0.25 nM) peptides inhibited RSK activity in a cell-free system, suggesting a direct effect (<xref ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5B</underline></xref>). The Ac-KThr217VD-CHO wt peptide also inhibited RSK, probably, because it binds to the kinase but cannot be phosphorylated by RSK given its small size (<xref ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5B</underline></xref>).</p><fig id="pone-0001372-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001372.g005</object-id><label>Figure 5</label><caption><title>C/EBP&#x003b2;-Ala217 inhibits RSK activation in hepatic stellate cells.</title><p>A. A phospho-RSK immunoblot was performed on RSK immunoprecipitates from protein lysates of purified HSC in an experiment conducted as described in (<xref ref-type="fig" rid="pone-0001372-g001">Fig. 1</xref>). Phosphorylated RSK (RSKp380) was decreased in HSC isolated from C/EBP&#x003b2;-Ala217 mice. C/EBP&#x003b2; and RSK were similar in the different experimental groups. &#x003b2;-Actin was used as an internal control for the immunoprecipitations. Results from triplicate samples of three independent experiments are shown. B. RSK activity was determined in a cell-free system as described in <xref ref-type="sec" rid="s4">Methods</xref>. Recombinant RSK was activated with ATP (125 &#x000b5;M) in the presence or absence of Ac-KThrVD-CHO (200 &#x000b5;M), Ac-KAlaVD-CHO (200 &#x000b5;M), or C/EBP&#x003b2;216-253-Ala217 (0.25 nM) peptides. Staurosporine was used as a control inhibitor (0.01 nM). All C/EBP&#x003b2; peptides inhibited RSK activity to a similar extent as staurosporine (P&#x0003c;0.01). Results from triplicate samples of two independent experiments are shown. C. Primary human C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> HSC were transfected with vectors (1 &#x000b5;g each) expressing green fluorescent protein with control wt RSK (GFP), a dominant negative RSK mutant, or C/EBP&#x003b2;-Ala217. Transfected HSC were selected by sorting for GFP, and cell lysates were immunoprecipitated with C/EBP&#x003b2; specific antibodies. C/EBP&#x003b2;-PhosphoThr217 (C/EBP&#x003b2;p217), and caspase 8 immunoblots were performed in C/EBP&#x003b2; immunoprecipitates. Dominant negative RSK or C/EPB&#x003b2;-Ala217 prevented C/EPB&#x003b2; phosphorylation and stimulated the association of unphosphorylated C/EBP&#x003b2; with active caspase 8. &#x003b2;-Actin was used as an internal control for the immunoprecipitations. Results from triplicate samples of three independent experiments are shown.</p></caption><graphic xlink:href="pone.0001372.g005"/></fig></sec><sec id="s2d"><title>C/EBP&#x003b2;-Ala217 transgene and unphosphorylated C/EBP&#x003b2;-Thr217 are associated with active caspase 8 and death receptor complex II proteins in HSC</title><p>Unexpectedly, we found that C/EBP&#x003b2;-Ala217 was present with active caspase 8 in HSC from C/EBP&#x003b2;-Ala217 mice after chronic CCl<sub>4</sub> administration and, to a lesser extent, after mineral oil administration (<xref ref-type="fig" rid="pone-0001372-g006"><underline>Figure 6A</underline></xref>). In contrast, the association between inactive procaspase 8 and C/EBP&#x003b2;-PhosphoThr217 (<xref ref-type="fig" rid="pone-0001372-g006"><underline>Figure 6A</underline></xref>), as well as that between C/EBP&#x003b2; and activated phospho-RSK (<xref ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5A</underline></xref>), increased in HSC of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice after chronic CCl<sub>4</sub> administration. Reciprocal immunoprecipitation with caspase 8 antibodies confirmed the presence of C/EBP&#x003b2;- Ala217 with active caspase 8 (<xref ref-type="fig" rid="pone-0001372-g006"><underline>Figure 6A</underline></xref>). RSK phosphorylation was inhibited in HSC from C/EBP&#x003b2;-Ala217 mice, indicating that C/EBP&#x003b2;-Ala217 not only associates with RSK but that it also decreases its phosphorylation and activation (<xref ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5A</underline></xref>). The hypothesis that inhibition of RSK by nonphosphorylatable C/EBP&#x003b2;-Ala217 is critical for caspase 8 activation is supported by the increased caspase 8 activation in HSC from C/EBP&#x003b2;-Ala217 mice after chronic CCl<sub>4</sub> administration (<xref ref-type="fig" rid="pone-0001372-g006"><underline>Figure 6A</underline></xref>).</p><fig id="pone-0001372-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001372.g006</object-id><label>Figure 6</label><caption><title>C/EBP&#x003b2;-Ala217 associates with active caspase 8 in hepatic stellate cells.</title><p>A. A caspase 8 immunoblot was performed on C/EBP&#x003b2; immunoprecipitates from protein lysates from samples described in (<xref ref-type="fig" rid="pone-0001372-g005">Fig 5 A</xref>). The association between C/EBP&#x003b2;-Ala217 with active caspase 8 was increased in HSC isolated from C/EBP&#x003b2;-Ala217 mice. Phosphorylated C/EBP&#x003b2;-Thr217 was decreased in HSC from C/EBP&#x003b2;-Ala217 mice treated with CCl<sub>4</sub>. C/EBP&#x003b2; and RSK were similar in the different experimental groups. &#x003b2;-Actin was used as an internal control for the immunoprecipitations. B. Reciprocal caspase 8 immunoprecipitation of experiment described in (A) confirmed the association of C/EBP&#x003b2;-Ala217 with active caspase 8. &#x003b2;-Actin was used as an internal control for the immunoprecipitations. C. Reciprocal caspase 8 immunoprecipitation of experiment described in (<xref ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5C</underline></xref>), confirmed the association of C/EBP&#x003b2;-Ala217 with active caspase 8. &#x003b2;-Actin was used as an internal control for the immunoprecipitations.</p></caption><graphic xlink:href="pone.0001372.g006"/></fig><p>Next, we studied whether blocking RSK activity results in activation of caspase 8. Activated primary human C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> HSC were transfected with vectors expressing green fluorescent protein with a control wt RSK (GFP), to facilitate cell sorting, with a dominant negative RSK mutant, or with the RSK-inhibitory dominant negative C/EBP&#x003b2;-Ala217. The HSC were activated on a collagen type 1 matrix, a condition that recapitulates the activation of HSC in vivo <xref ref-type="bibr" rid="pone.0001372-AnkomaSey1">&#x0005b;9&#x0005d;</xref>, and identified by their expression of GFAP <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>.</p><p>As expected, C/EBP&#x003b2;-PhosphoThr266 (identical to mouse phosphoacceptor Thr217) was markedly decreased in activated human HSC expressing either the RSK mutant or C/EBP&#x003b2;-Ala217. Moreover, we found that unphosphorylated C/EBP&#x003b2; was associated active caspase 8 (<xref ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5C</underline></xref>). The RSK phosphoacceptor site in C/EBP&#x003b2; is identical in mouse and human, it is evolutionarily conserved <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref>, and essential for HSC survival upon their activation <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>.</p><p>C/EBP&#x003b2;-Ala266 associated with active caspase 8, in cells expressing the dominant negative RSK (<xref ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5C</underline></xref>), which prevents C/EBP&#x003b2; phosphorylation on Thr266 by RSK. In contrast, in the control cells expressing GFP and RSK wt, C/EBP&#x003b2; was phosphorylated and associated with procaspase 8 (<xref ref-type="fig" rid="pone-0001372-g005"><underline>Figure 5C</underline></xref>), as we reported previously <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>. Reciprocal immunoprecipitation with caspase 8 specific antibodies confirmed the presence of unphosphorylated C/EBP&#x003b2; with active caspase 8 (<xref ref-type="fig" rid="pone-0001372-g006"><underline>Figure 6 B and C</underline></xref>). After blocking the RSK-C/EBP&#x003b2; phosphorylation cascade in activated HSC, with either an ERK1/2 inhibitor or a cell permeant Ac-KAla217VD-CHO peptide, which contains the mutated C/EBP&#x003b2;-Ala217 phosphoacceptor, unphosphorylated C/EBP&#x003b2; became associated with other members of the death receptor complex II, such as TNFR1, TRAF2, TRADD and RIP <xref ref-type="bibr" rid="pone.0001372-Micheau1">&#x0005b;29&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0001372-g007"><underline>Figure 7A, B, and C</underline></xref>). These associations were identified in C/EBP&#x003b2;, TNFR1, TRAF2, TRADD and RIP immunoprecipitations (<xref ref-type="fig" rid="pone-0001372-g007"><underline>Figure 7</underline></xref><xref ref-type="supplementary-material" rid="pone.0001372.s004"><underline> and Figure S3</underline></xref>). The Ac-KAla217VD-CHO peptide is cell permeant due to its N-terminus acetyl group, as it has been documented for other peptides used as substrate or inhibitors of caspases <xref ref-type="bibr" rid="pone.0001372-Leite1">&#x0005b;<underline>30</underline>&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Zhang1">&#x0005b;31&#x0005d;</xref>.</p><fig id="pone-0001372-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001372.g007</object-id><label>Figure 7</label><caption><title>RSK inhibition induces the association of C/EBP&#x003b2; with active caspase 8, TNFR1, TRAF2, TRADD and RIP.</title><p>A. TRADD, C/EBP&#x003b2;, RIP and caspase 8 immunoblots were performed on C/EBP&#x003b2; immunoprecipitates from primary human HSC treated with an ERK1/2 inhibitor (10 &#x000b5;M) or the cell permeant Ac-KA217VD-CHO peptide (200 &#x000b5;M). Blocking the phosphorylation of C/EBP&#x003b2; by RSK with the ERK1/2 inhibitor or the cell permeant Ac-KA217VD-CHO (KAVD) peptide, increased the association between C/EBP&#x003b2;, active caspase 8, TRADD and RIP. &#x003b2;-Actin was used as an internal control for the immunoprecipitations. B. TNFR1 and C/EBP&#x003b2; immunoblots were performed on C/EBP&#x003b2; immunoprecipitates from HSC isolated from mice treated with CCl<sub>4</sub> for 12 or 16 weeks as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref>. Blocking the phosphorylation of C/EBP&#x003b2; by RSK with C/EBP&#x003b2;-Ala217 transgene or the cell permeant Ac-KA217VD-CHO peptide increased the association between C/EBP&#x003b2; and TNFR1. &#x003b2;-Actin was used as an internal control for the immunoprecipitations. C. TRAF2 and C/EBP&#x003b2; immunoblots were performed on C/EBP&#x003b2; immunoprecipitates from HSC isolated from mice treated with CCl<sub>4</sub> for 12 or 16 weeks as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref>. Blocking the phosphorylation of C/EBP&#x003b2; by RSK with C/EBP&#x003b2;-Ala217 transgene or the cell permeant Ac-KA217VD-CHO peptide increased the association between C/EBP&#x003b2; and TRAF2. &#x003b2;-Actin was used as an internal control for the immunoprecipitations. D. Cytochrome C and Apaf1 immunoblots were performed on cytochrome C immunoprecipitates in livers from mice treated with CCl<sub>4</sub> for 12 or 16 weeks as described in <xref ref-type="sec" rid="s4">Materials and Methods</xref>. Blocking the phosphorylation of C/EBP&#x003b2; by RSK with C/EBP&#x003b2;-Ala217 transgene or the cell permeant Ac-KA217VD-CHO peptide increased the association between cytochrome C and Apaf1. &#x003b2;-Actin was used as an internal control for the immunoprecipitations.</p></caption><graphic xlink:href="pone.0001372.g007"/></fig></sec><sec id="s2e"><title>A cell-permeant C/EBP&#x003b2;-Ala217 peptide stimulates active caspase 8 and cell death in collagen type 1-induced activation of cultured HSC</title><p>We corroborated the activation of caspase 8 in HSC, under conditions that prevented phosphorylation of C/EBP&#x003b2;, as described above, by demonstrating the association between cytochrome C with Apaf-1 (<xref ref-type="fig" rid="pone-0001372-g007"><underline>Figure 7D</underline></xref>), which reflects a downstream amplification effect of active caspase 8 on mitochondrial apoptotic pathways <xref ref-type="bibr" rid="pone.0001372-Spierings1">&#x0005b;32&#x0005d;</xref>. The reciprocal analysis could not be performed since Apaf-1 antibodies are not suitable for immunoprecipitation. Moreover, inhibition of the RSK-C/EBP&#x003b2; phosphorylation cascade with the cell permeant C/EBP&#x003b2;-Ala217 peptide, Ac-KAla217VD-CHO induced expression of the apoptosis effector caspase 3 in cultured, activated mouse HSC, but not in primary mouse hepatocytes (<xref ref-type="supplementary-material" rid="pone.0001372.s005"><underline>Figure S4</underline></xref>). These findings suggest a selective induction of apoptotic pathways by C/EBP&#x003b2;-Ala217 peptides in cultured activated HSC but not in cultured primary hepatocytes. This conclusion is supported by the apoptotic changes in activated HSC but not hepatocytes of C/EBP&#x003b2;-Ala217 transgenic mice treated with CCl<sub>4</sub>, and by the lack of apoptosis of normal quiescent HSC and hepatocytes of C/EBP&#x003b2;-Ala217 transgenic mice not treated with CCl<sub>4</sub>. In addition, after CCl<sub>4 </sub>treatment, hepatocyte injury and hepatic inflammation are decreased in C/EBP&#x003b2;-Ala217 transgenic mice compared to control C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice, arguing for a protective rather than an apoptotic effect on hepatocytes.</p><p>Our findings in cell-free, cellular and animal models strongly support the main hypothesis, and suggest a novel, physiological role for unphosphorylated C/EBP&#x003b2; on caspase 8 activation. Indeed, we found that caspase 8 activation is stimulated by C/EBP&#x003b2;-Ala217 in HSC from C/EBP&#x003b2;-Ala217 mice treated with CCl<sub>4 </sub>(<xref ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8A</underline></xref>). In addition, we determined that the peptide enhanced the activity of recombinant caspase 8 in a cell-free system at picomolar concentrations (<xref ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8B</underline></xref>). To our knowledge, the C/EBP&#x003b2;-Ala217 peptides are the first reported compounds to directly enhance caspase 8 activation (G Salvesen, personal communication).</p><fig id="pone-0001372-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001372.g008</object-id><label>Figure 8</label><caption><title>The RSK-inhibitory peptide blocks hepatic stellate cell activation and liver fibrosis induced by CCl<sub>4</sub>.</title><p>A Caspase 8 activity was measured in lysates from HSC isolated from C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b; </sup>&#x0005b;wt&#x0005d; and C/EBP&#x003b2;-Ala217 mice untreated or treated with CCl<sub>4</sub> for 24 hr. Caspase activity was increased in C/EBP&#x003b2;-Ala217 mice treated with CCl<sub>4</sub>. Results from triplicate samples of two independent experiments are shown. B. Caspase activation in a cell-free system was determined as described in <xref ref-type="sec" rid="s4">Methods</xref>. The Ac-KAla217VD-CHO peptide enhanced the activation of caspase 8 at picomolar concentrations. Baseline caspase 8 activity was 3.8 U (100&#x00025;). Results from triplicate samples of three independent experiments are shown (<italic>P&#x0003c;0.01</italic> for the Ac-KAla217VD-CHO peptide). C. Animals received a single injection of CCl<sub>4 </sub>or mineral oil as described in <xref ref-type="sec" rid="s4">Methods</xref>. &#x003b1;-SMA (red) and C/EBP&#x003b2;-PhosphoThr217 (green) were identified as described in <xref ref-type="sec" rid="s4">Materials and methods</xref>. Treatment with the cell permeant Ac-KAla217VD-CHO peptide blocked the expression of &#x003b1;-SMA and C/EBP&#x003b2;-PhosphoThr217. D. PCNA (red) and active caspase 3 (green) were identified as described in <xref ref-type="sec" rid="s4">Materials and methods</xref>. Treatment with the Ac-KAla217VD&#x02013;CHO peptide blocked the expression of PCNA and induced active caspase 3. E. C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> (wt) mice with severe liver fibrosis after treatment with CCl<sub>4</sub> for 8 weeks, while continuing on CCl<sub>4</sub>, received the RSK inhibitory peptide (5 &#x000b5;g IP, three times/week, for week 9 followed by 1 &#x000b5;g IP, three times/week for weeks 10&#x02013;12 or 10&#x02013;16). These are representative Mallory's trichrome stain for liver fibrosis (in blue). All control mice (<italic>n</italic>: 8 at 8-weeks; <italic>n</italic>: 8 at 12-weeks; and <italic>n</italic>: 8 at 16-weeks) developed severe liver fibrosis, while mice receiving the RSK-inbitory peptide (<italic>n</italic>: 8 at 12-weeks; and <italic>n</italic>: 8 at 16-weeks) had no fibrosis or only minimal liver fibrosis (<italic>P&#x0003c;0.01</italic>). F. Analysis of hepatic collagen content by the Sirius red collagen&#x02013;binding assay showed a &#x0223c;2.5 to 3-fold increase in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice treated with CCl<sub>4</sub> (<italic>n</italic>: 8 for 8 weeks; <italic>n</italic>: 8 for 12 weeks and <italic>n</italic>: 8 for the 16 weeks), compared to animals also receiving the RSK-inbitory peptide (<italic>n</italic>: 6 for 12weeks; <italic>n</italic>: 8 for 16 weeks; <italic>P&#x0003c;0.01</italic>). G. Analysis of hepatic collagen content by the hydroxyproline assay, showed a 2.2-, 3.5- and 5.3-fold increase in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice treated with CCl<sub>4</sub>, respectively (<italic>n</italic>: 8 for 8 weeks; <italic>n</italic>: 7 for 12 weeks and <italic>n</italic>: 7 for the 16 weeks), compared to animals also receiving the RSK-inbitory peptide (<italic>n</italic>: 6 for 12weeks; <italic>n</italic>: 8 for 16 weeks; <italic>P&#x0003c;0.01</italic>).</p></caption><graphic xlink:href="pone.0001372.g008"/></fig><p>These experiments provided a strong proof-of-principle that RSK activation mediates the signaling required for liver inflammation and liver fibrosis.</p></sec><sec id="s2f"><title>A cell-permeant C/EBP&#x003b2;-Ala217 peptide stimulates cell death in hepatotoxin-induced activation of HSC</title><p>Because in preliminary studies the cell permeant tetrapeptide Ac-KAla217VD-CHO was effective in inducing apoptosis of cultured activated HSC <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>, we studied whether this peptide would also be effective in inducing apoptosis of activated HSC in a physiologically relevant animal model of liver injury <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Rudolph1">&#x0005b;16&#x0005d;</xref>. To activate HSC, we administered a single dose of CCl<sub>4 </sub>to C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> (wt) mice, while control mice received the mineral oil vehicle <xref ref-type="bibr" rid="pone.0001372-Rudolph1">&#x0005b;16&#x0005d;</xref>. Six hours later, animals received an intraperitoneal injection of the cell permeant Ac-KAla217VD-CHO peptide <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref> (100 &#x000b5;g) or saline vehicle (100 &#x000b5;l). In preliminary studies, we found that 1&#x02013;100 &#x000b5;g of peptide dose provided adequate bioavailability (M B, unpublished observations). Animals were sacrificed at 24 h. Acute CCl<sub>4</sub> administration induced both activation and proliferation of HSC (among other hepatic cells), judging by the expression of &#x003b1;SMA and PCNA, as determined by confocal microscopy (<xref ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8C and D</underline></xref>).</p><p>HSC activation and proliferation were blocked by treatment with the Ac-KAla217VD-CHO peptide, but not by treatment with saline (<xref ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8C and D</underline></xref>). Similarly to our findings of RSK inhibition in cell-free, cultured primary stellate cells and in C/EBP&#x003b2;-Ala217 transgenic mice, the Ac-KAla217VD-CHO peptide prevented the phosphorylation of C/EBP&#x003b2; on Thr217 in HSC activated by the liver injury induced by CCl<sub>4</sub> (<xref ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8C</underline></xref>). Further, and in agreement to our findings of the increased caspase 8 activation in cell-free, cultured primary stellate cells and in C/EBP&#x003b2;-A217 transgenic mice, the Ac-KAla217VD-CHO peptide stimulated the apoptotic pathway of C/EBP&#x003b2; wt HSC as indicated by the presence of active caspase 3 (<xref ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8 D</underline></xref>).</p></sec><sec id="s2g"><title>A cell-permeant C/EBP&#x003b2;-Ala217 peptide inhibits progression and stimulates regression of hepatotoxin-induced liver fibrosis</title><p>Activation of stellate cells is responsible for the development of liver fibrosis in chronic liver diseases of all causes <xref ref-type="bibr" rid="pone.0001372-Chung1">&#x0005b;3&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Chojkier1">&#x0005b;4&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Bataller1">&#x0005b;8&#x0005d;</xref>, and remarkably, HSC clearance by apoptosis may allow recovery from liver injury and reversal of liver fibrosis <xref ref-type="bibr" rid="pone.0001372-Iredale1">&#x0005b;33&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Friedman3">&#x0005b;34&#x0005d;</xref>.</p><p>Given the effective blocking by the RSK-inhibitory peptide of molecular pathways leading to liver fibrosis in an acute CCl<sub>4 </sub>model of liver injury and fibrogenesis, we asked whether these effects would occur in a model of established liver fibrosis due to chronic liver injury, reproducing the disease state of patients with severe liver injury and fibrosis.</p><p>Therefore, C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice with severe liver fibrosis, after receiving CCl<sub>4</sub> for 8 weeks, were treated with the RSK inhibitory peptide for an additional 4 or 8 weeks (5 &#x000b5;g IP, three times/week, for week 9, followed by 1 &#x000b5;g IP, three times/week for weeks 10&#x02013;12 or 10&#x02013;16), while continuing to induce liver injury and fibrosis with CCl<sub>4</sub>. Treatment of animals with liver fibrosis with the peptide, while continuing to receive CCl<sub>4</sub>, prevented the progression and induced regression of liver fibrosis compared to control mice treated with CCl<sub>4</sub>. At week-12 or week-16, there was a marked regression of liver fibrosis judging by the trichrome stain (<xref ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8E</underline></xref>) and Sirius red staining (<underline>Figure S5</underline>). All control mice (<italic>n</italic>: 22) had severe liver fibrosis, while all mice that received the RSK-inhibitory peptide had minimal or no liver fibrosis. We confirmed these findings by quantitative analysis of liver collagen with the Sirius red binding assay (<italic>P</italic>&#x0003c;0.01) <xref ref-type="bibr" rid="pone.0001372-Jimenez1">&#x0005b;19&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8F</underline></xref>). Analysis of hepatic collagen content by the hydroxyproline assay (<xref ref-type="fig" rid="pone-0001372-g008"><underline>Figure 8G</underline></xref>), showed a 2.2-, 3.5-, and 5.3-fold increase in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice treated with CCl<sub>4</sub> for 8, 12 and 16 weeks, respectively (<italic>n</italic>: 8 for 8 weeks; <italic>n</italic>: 7 for 12 weeks and <italic>n</italic>: 7 for the 16 weeks), compared to animals treated with the RSK-inhibitory peptide (<italic>n</italic>: 6 for 12 weeks; <italic>n</italic>: 8 for 16 weeks; <italic>P</italic>&#x0003c;0.01).</p><p>In agreement with the results observed after CCl<sub>4</sub> treatment in mice expressing the C/EBP&#x003b2;-Ala217 transgene, treatment with the RSK-inhibitory peptide of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice with severe liver fibrosis induced by CCl<sub>4</sub>, while continuing to receive CCl<sub>4,</sub> reduced the following: i) expression of liver fibrogenic indicators such as collagen &#x003b1; 1 type 1 mRNA (<italic>P</italic>&#x0003c;0.05), &#x003b1;-SMA mRNA (activated HSC) (<italic>P</italic>&#x0003c;0.05), and TGF-&#x003b2; mRNA (fibrogenic cytokine) (<italic>P</italic>&#x0003c;0.01) (<xref ref-type="fig" rid="pone-0001372-g002"><underline>Figure 2A, B, and C</underline></xref>); and ii) recruitment of CD-68&#x0002b; inflammatory cells to the liver (<xref ref-type="fig" rid="pone-0001372-g003"><underline>Figure 3A</underline></xref>).</p></sec><sec id="s2h"><title>Increased expression of active RSK and C/EBP&#x003b2;-PhosphoThr266 in activated HSC of human liver fibrosis</title><p>The RSK phosphoacceptor site in C/EBP&#x003b2; is identical in mouse and human, it is evolutionarily conserved <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref>, and necessary for HSC survival upon their activation <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>. The RSK pathway may be critical for HSC activation induced by liver injury, because expression of a catalytically inactive mutant RSK <xref ref-type="bibr" rid="pone.0001372-Nakajima1">&#x0005b;15&#x0005d;</xref>, blocked proliferation and survival of cultured HSC upon their activation by collagen type 1 <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>.</p><p>To assess the relevance to human liver fibrosis of the cellular and animal models of liver fibrosis, we analyzed, in preliminary studies, the role of activated RSK and phosphorylated C/EBP&#x003b2; on Thr266 (identical to mouse Thr217 phosphoacceptor) as possible mechanisms leading to increased liver fibrosis in four patients with chronic hepatitis C viral infection that resulted in severe liver fibrosis (53&#x000b1;17 years) (see <xref ref-type="sec" rid="s4">Materials and methods</xref>). Liver biopsies from hepatitis C patients afflicted with severe liver fibrosis (METAVIR scores of 3 or 4) displayed a high level expression of both active, phosphorylated RSK and phosphorylated human C/EBP&#x003b2; on Thr266 in activated HSC within the fibrous tissue, compared with samples from three control patients (60&#x000b1;13 years) as identified by confocal scanning microscopy with specific antibodies against RSK-PhosphoSer380, C/EBP&#x003b2;-PhosphoThr266, and glial fibrillary protein for HSC <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0001372-g009"><underline>Figure 9 A and B</underline></xref>).</p><fig id="pone-0001372-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001372.g009</object-id><label>Figure 9</label><caption><title>Increased expression of active RSK and C/EBP&#x003b2;-PhosphoThr217 in activated hepatic stellate cells of human liver fibrosis.</title><p>Representative confocal microscopy of 4 patients with severe liver fibrosis and 3 control subjects. A. Activated HSC, identified by confocal microscopy for their morphology and fluorescence for glial fibrillary acidic protein (GFAP; red), displayed activated RSK-PhosphoSer380 in livers of patients with severe liver fibrosis (lower panel) but not in the livers of control subjects (upper panel). Colocalization of RSK-PhosphoSer380 and GFAP is shown in yellow (merge). Nuclei are identified with TO-PRO-3 (blue). Only background staining was observed when omitting the first antibody. B. C/EBP&#x003b2;-PhosphoThr217 (green) was present in activated HSC only in livers of patients with liver fibrosis (lower panel). Colocalization of C/EBP&#x003b2;-PhosphoThr217 and GFAP (red) is shown in yellow (merge). Nuclei are identified with TO-PRO-3 (blue).</p></caption><graphic xlink:href="pone.0001372.g009"/></fig><p>Thus, our findings in liver biopsies from patients with liver fibrosis are congruent with the hypothesis we developed in cell-free, cellular and animal models that RSK activation and its phosphorylation of C/EBP&#x003b2; in activated HSC may be important in the development of human liver fibrosis.</p></sec></sec><sec id="s3"><title>Discussion</title><p>Activation of HSC is responsible for the development of liver fibrosis in chronic liver diseases of all causes <xref ref-type="bibr" rid="pone.0001372-Chung1">&#x0005b;3&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Chojkier1">&#x0005b;4&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Bataller1">&#x0005b;8&#x0005d;</xref>, and remarkably, HSC clearance by apoptosis may allow recovery from liver injury and reversal of liver fibrosis <xref ref-type="bibr" rid="pone.0001372-Iredale1">&#x0005b;33&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Friedman3">&#x0005b;34&#x0005d;</xref>.</p><p>In this study we show that activation of RSK and phosphorylation of C/EBP&#x003b2; on Thr217 in activated HSC is critical for the progression of liver fibrosis. We used the classical CCl<sub>4</sub>-induced liver injury and fibrosis model in mice <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Rudolph1">&#x0005b;16&#x0005d;</xref>, primary mouse and human HSC <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>, and cell-free systems to investigate the role of RSK and phosphorylation of C/EBP&#x003b2; on Thr217 in the activation of HSC and liver fibrosis. It would be important to determine whether RSK and phosphorylation of C/EBP&#x003b2; are also critical in other animal models that reflect other causes of human liver fibrosis, such as biliary cirrhosis, alcoholic liver disease, immune liver injury and genetic iron overload <xref ref-type="bibr" rid="pone.0001372-Chung1">&#x0005b;3&#x0005d;</xref>. Any one of these studies will require as extensive an analysis as that performed with the CCl<sub>4 </sub>model of liver fibrosis.</p><p>We found that mice expressing the RSK-inhibitory C/EBP&#x003b2;-Ala217 transgene were refractory to the induction of HSC activation and proliferation by CCl<sub>4</sub> treatment. After chronic CCl<sub>4</sub> administration, C/EBP&#x003b2; was phosphorylated on Thr217 in HSC of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice, but not of C/EBP&#x003b2;-Ala217 mice. C/EBP&#x003b2;-Ala217 binding to, and blocking, RSK phosphorylation results in decreased phosphorylation of C/EBP&#x003b2; on Thr217, and presumably, other target survival proteins by activated RSK. Moreover, chronic CCl<sub>4</sub> treatment induced the apoptotic cascade in HSC in the livers of C/EBP&#x003b2;-Ala217 mice, but not C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice, as determined by the presence of active caspase 8 and 3.</p><p>C/EBP&#x003b2;-Ala217 was present within the death receptor complex II, with active caspase 8, and was linked to apoptosis of activated HSC, freshly isolated from transgenic mice. After blocking the RSK-C/EBP&#x003b2; phosphorylation cascade in activated human HSC in culture, with either an ERK1/2 inhibitor or a cell permeant RSK-inhibitory peptide, Ac-KAla217VD-CHO, unphosphorylated C/EBP&#x003b2; became associated with other members of the death receptor complex II, such as TNFR1, TRAF2, TRADD and RIP <xref ref-type="bibr" rid="pone.0001372-Micheau1">&#x0005b;29&#x0005d;</xref>. The combined results suggest a functional link between inactive RSK and the active caspase 8 complex II. Further, inactive RSK and active caspase 8 are co-immunoprecipitated with C/EBP&#x003b2;-Ala217 or unphosphorylated C/EBP&#x003b2;, suggesting also a physical link. However, identification of a putative RSK/caspase 8 complex would require crystallographic analysis.</p><p>In support of our proposed role of unphosphorylated and phosphorylated C/EBP&#x003b2;-Thr217 on the modulation of HSC survival following their activation by liver injury, expression of the dominant positive phosphorylation mimic C/EBP&#x003b2;-Glu217 <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref> enhances survival of cultured progenitor neuronal cells <xref ref-type="bibr" rid="pone.0001372-Menard1">&#x0005b;35&#x0005d;</xref> while C/EBP&#x003b2;<sup>&#x02212;/&#x02212;</sup> macrophages display defective bacterial killing and tumor cytotoxicity <xref ref-type="bibr" rid="pone.0001372-Tanaka1">&#x0005b;36&#x0005d;</xref>. A corollary of our study is that mice expressing the C/EBP&#x003b2;-Glu217 transgene would be more susceptible to HSC activation and liver fibrosis induced by liver injury and inflammation. Indeed, this seems to be the case in preliminary studies with these novel transgenic mice (M.B, unpublished observations).</p><p>Although the association between C/EBP&#x003b2;-PhosphoThr217 and inactive procaspase 8 is linked to the inhibition of active caspase 8 <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>, the precise molecular mechanisms by which phosphorylated C/EBP&#x003b2; prevents liver injury-induced HSC apoptosis have not been characterized yet. Phosphorylated C/EBP&#x003b2; could induce the inhibition of pro-apoptotic proteins, such as p53 <xref ref-type="bibr" rid="pone.0001372-Yoon1">&#x0005b;37&#x0005d;</xref> or the activation of survival proteins, such as MnSOD <xref ref-type="bibr" rid="pone.0001372-Ranjan1">&#x0005b;38&#x0005d;</xref>, or FLIP <xref ref-type="bibr" rid="pone.0001372-Micheau1">&#x0005b;29&#x0005d;</xref>. Alternatively, granzyme B rather than caspase 8 could be the major target of phosphorylated C/EBP&#x003b2;-Thr217, as we suggested previously for HSC apoptosis/survival <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>.</p><p>The hepatotoxin CCl<sub>4</sub> induced severe liver fibrosis in C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice but not in mice expressing C/EBP&#x003b2;-Ala217, a non-phosphorylatable RSK-inhibitory transgene as detected by morphological, semi quantitative and quantitative assays. Blocking phosphorylation of C/EBP&#x003b2;-Thr217 through the inhibition of RSK activity with the C/EBP&#x003b2;-Ala217 transgene or by C/EBP&#x003b2; gene knock-out decreases the fibrotic response of the liver to chronic injury. These findings indicate that the RSK phosphoacceptor site in C/EBP&#x003b2;, which is identical in mouse and human <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref>, is essential for HSC survival upon their activation in chronic liver injury in mice. Further, the decreased fibrotic response of the liver to the hepatotoxin in C/EBP&#x003b2; <sup>&#x02212;/&#x02212;</sup> mice suggests that the critical target of RSK in activated HSC is C/EBP&#x003b2;-Thr217 rather than other RSK phosphoacceptors in c-Fos, CREB, CBP or other proteins <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001372-SassoneCorsi1">&#x0005b;14&#x0005d;</xref>.</p><p>Because liver inflammation induces liver injury and liver fibrosis <xref ref-type="bibr" rid="pone.0001372-Friedman3">&#x0005b;34&#x0005d;</xref> we assessed the degree of liver injury and the inflammatory response to the hepatotoxin. We found decreased liver injury and inflammation in response to CCl<sub>4</sub> treatment in mice expressing the C/EBP&#x003b2;-Ala217 transgene. Our data suggest that in addition to increased HSC apoptosis, partial resistance to liver injury and inflammation may contribute to the prevention of liver fibrosis in C/EBP&#x003b2;-Ala217 mice. A decreased inflammatory response, mediated at least in part by monocytes/macrophages in the livers of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice, may be responsible for the decreased liver injury in C/EBP&#x003b2;-Ala217 mice, since RSK inhibition also affected the recruitment of CD-68&#x0002b; inflammatory cells to the liver. Our results are congruent with the proposed role of macrophages as a major contributor to liver injury and liver fibrosis <xref ref-type="bibr" rid="pone.0001372-Chojkier2">&#x0005b;20&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Matsuoka1">&#x0005b;22&#x0005d;</xref>.</p><p>Similarly to our findings of RSK inhibition in cell-free, cultured primary stellate cells and in C/EBP&#x003b2;-Ala217 transgenic mice, the cell permeant Ac-KAla217VD-CHO peptide prevented the phosphorylation of C/EBP&#x003b2; on Thr217 in HSC activated by the liver injury induced by CCl<sub>4</sub>. Further, and in agreement to our findings of the increased caspase 8 activation in cell-free, cultured primary stellate cells and in C/EBP&#x003b2;-A217 transgenic mice, the Ac-KAla217VD-CHO peptide stimulated the apoptotic pathway of C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> HSC as indicated by the presence of active caspase 8 and 3.</p><p>C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice with severe liver fibrosis induced by an 8-week CCl<sub>4</sub> treatment, while continuing on CCl<sub>4</sub>, were treated with the cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The peptide inhibited RSK activation, stimulated apoptosis of HSC and blocked active fibrogenesis, preventing progression and inducing regression of liver fibrosis compared to control mice treated with CCl<sub>4</sub>. Because the resulting activation of HSC and liver fibrosis is similar in any type of chronic liver injury, these results suggest that the inhibition of both RSK and its phosphorylation of C/EBP&#x003b2; may be effective in preventing/regressing liver fibrosis in animal models that reflect other causes of human liver fibrosis, such as biliary cirrhosis, alcoholic liver disease, immune liver injury, and genetic iron overload <xref ref-type="bibr" rid="pone.0001372-Chung1">&#x0005b;3&#x0005d;</xref>.</p><p>To assess the relevance of the cellular and animal models of liver fibrosis to human liver fibrosis, we analyzed, in preliminary studies, the role of activated RSK and phosphorylated C/EBP&#x003b2; on Thr266 (identical to mouse Thr217 phosphoacceptor) as possible mechanisms leading to increased liver fibrosis. Liver biopsies from hepatitis C patients afflicted with severe liver fibrosis displayed a high level expression of both active, phosphorylated RSK and phosphorylated human C/EBP&#x003b2; on Thr266 in activated HSC within the fibrous tissue, compared with samples from control patients. Thus, our findings in liver biopsies from patients with liver fibrosis are congruent with the hypothesis we developed in cell-free, cellular and animal models implicating RSK activation and its phosphorylation of C/EBP&#x003b2; in activated HSC in the development of human liver fibrosis.</p><sec id="s3a"><title>Clinical Implications</title><p>Our data indicate that the RSK-C/EBP&#x003b2; phosphorylation pathway in HSC is activated in severe human liver fibrosis, and that it is critical for the progression of liver injury to severe liver fibrosis and cirrhosis in an animal model.</p><p>This study suggest that blocking RSK activity inhibits fibrogenesis directly by inducing HSC apoptosis, and indirectly, by reducing liver injury and inflammation. There is no available treatment for liver fibrosis. We speculate that these findings may facilitate the development of small molecules potentially useful in the prevention and treatment of liver fibrosis.</p><p>Both regression of liver fibrosis as well as lack of progression of liver fibrosis, in spite of continued liver injury, as we clearly documented in our study, are considered important clinical targets for patients with chronic liver disease and liver fibrosis <xref ref-type="bibr" rid="pone.0001372-Friedman3">&#x0005b;34&#x0005d;</xref>. Finally, blocking the progression of liver fibrosis would decrease development of primary liver cancer in these patients since the majority of hepatocellular carcinomas arise in cirrhotic livers <xref ref-type="bibr" rid="pone.0001372-3">&#x0005b;39&#x0005d;</xref>.</p></sec></sec><sec sec-type="materials|methods" id="s4"><title>Material and Methods</title><sec id="s4a"><title>Construction of C/EBP&#x003b2;-Ala217 mice</title><p>The Animal Protocol was approved by the VA Healthcare Center's Veterinarian Medical Unit. Transgenic mice expressing C/EBP&#x003b2;-Ala217, a dominant negative, nonphosphorylatable mutation of the C/EBP&#x003b2;-Thr217 phosphoacceptor, were generated as described previously <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref> and back-crossed to the parental wild-type inbreed FVB mice for &#x0003e;4 generations. The mouse C/EBP&#x003b2; cDNA was amplified by PCR to mutate Thr217. The primers used to mutate Thr217 to Ala217 were S 5&#x02032;-GCC AAG GCC AAG AAG GCG GTG GAC AAG CTG AGC -3&#x02032;and AS 5&#x02032;-GCT CAG CTT GTC CAC CGC CTT CTT GGC CTT GGC -3&#x02032;. C/EBP&#x003b2; was removed from pEVRF0 with Apa I and Nhe I and cloned into pHM6 vector (Boehringer-Mannheim, cat. # 1814664) in order to add an RSV promoter upstream to the C/EBP&#x003b2; start site. C/EBP&#x003b2; was removed from this new construct with Bsa I and Bsp. The 982 bp insert was cloned into mammalian vector pOP13CAT (Stratagene) from which the CAT portion had been previously removed. DNA for pronuclear injection was purified over a CsCl gradient and digested with Ssp I and EclHK I. The 3.6 Kb fragment was separated on gel electrophoresis on a 0.8&#x00025; gel with no Ethidium Bromide. The appropriate band was removed and electro eluted from the gel using the Elutrap apparatus from Schleicher &#x00026; Schuell. The eluted DNA was purified with a Qiagen-20 column, precipitated with isopropanol and dissolved in 7.5 mM TRIS pH 7.4, 0.15 mM EDTA. All solutions were prepared with tissue grade water, endotoxin tested (Gibco). Finally the DNA was dialyzed and injected into fertilized ova at a concentration of 1.8 &#x000b5;g/ml, at the Transgenic Mouse Core Facilities, University of California, San Diego. The presence of the <italic>rsv</italic> gene was used to identify these transgenic mice by PCR, and 3 positive mice resulted. The primer sequences for the RSV PCR were custom designed (RSV.2271 TAGGGTGTGTTTAGGCGAAA sense and RSV.2510 TCTGTTGCCTTCCTAATAAG antisense). The PCR reagents were all from Qiagen. Transgene-bearing founder mice were mated with FVB mice. All founder mice produced viable offspring. This line was bred by mating transgene-positive mice with wild-type FVB and backcrossed to FVB for at least four generations.</p></sec><sec id="s4b"><title>Animal Procedures</title><p>In the chronic exposure to the hepatotoxin, C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup>, C/EBP&#x003b2;Ala217 and C/EBP&#x003b2;<sup>&#x02212;/&#x02212;</sup> mice <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Screpanti1">&#x0005b;40&#x0005d;</xref> (23&#x02013;27 g) each received intraperitoneal injections of CCl<sub>4</sub> or mineral oil (50 &#x000b5;l) only once or weekly (for up to 16 weeks). In other chronic experiments, C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice (25 g) each received intraperitoneal injections of CCl<sub>4</sub> or mineral oil (50 &#x000b5;l) weekly (for up to 16 weeks), but after 8 weeks, animals received either saline (control) or the cell permeant Ac-KAla217VD-CHO (American Peptide) <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref> (5 &#x000b5;g IP, three times/week, for week 9, followed by 1 &#x000b5;g IP, three times/week for weeks 10&#x02013;12 or 10&#x02013;16) while continuing to induce liver injury and fibrosis with CCl<sub>4</sub>. In the chronic experiments, animals were sacrificed 24 hr after the last CCl<sub>4</sub> injection</p><p>In the acute exposure to the hepatotoxin, animals received the cell permeant Ac-KAla217VD-CHO <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref> (100 &#x000b5;g intraperitoneally) at 18 hr and animals were sacrificed at 24 hr <xref ref-type="bibr" rid="pone.0001372-Buck3">&#x0005b;41&#x0005d;</xref>.</p></sec><sec id="s4c"><title>Cell cultures</title><p>Adult C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> and C/EBP&#x003b2;-Ala217 transgenic mice were used for the isolation of hepatic stellate cells as described <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>. Stellate cells were prepared, by <italic>in situ</italic> perfusion and single-step density Nycodenz gradient (Accurate Chemical &#x00026; Scientific Corp., Westbury, New York), as described previously <xref ref-type="bibr" rid="pone.0001372-Lee1">&#x0005b;6&#x0005d;</xref>. Stellate cells were identified by their typical autofluorescence at 328nm excitation wavelength, staining of lipid droplets by oil red, and immunohistochemistry with a monoclonal antibody against desmin. Greater than 95&#x00025; of the isolated cells were stellate cells.</p><p>Primary mouse stellate cells freshly isolated from C/EBP&#x003b2;<sup>&#x0002b;/&#x0002b;</sup> mice and activated by collagen type 1 matrix <xref ref-type="bibr" rid="pone.0001372-Lee1">&#x0005b;6&#x0005d;</xref>, were transfected with vectors expressing RSK wild type, a catalytically inactive, dominant negative RSK mutant, or C/EBP&#x003b2;-Ala217 together with GFP <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>. Transfected stellate cells were selected by sorting for GFP, and cell lysates were immunoprecipitated with C/EBP&#x003b2; specific antibodies. In other experiments, stellate cells were incubated for 24 hr with an ERK1/2 inhibitor (Calbiochem 328006) (10 &#x000b5;M), or the KAVD peptide (200 &#x000b5;M).</p></sec><sec id="s4d"><title>Microscopy</title><p>Fluorescent labels were observed using antibodies against C/EBP&#x003b2;, RSKPhosphoSer380, &#x003b1;-SMA, PCNA (Santa Cruz Biotechnology, Santa Cruz, California), active caspase 3 (PharMingen, San Diego, California) or C/EBP&#x003b2;-PhosphoThr217 <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref> in a laser confocal microscope <xref ref-type="bibr" rid="pone.0001372-Buck1">&#x0005b;5&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Buck4">&#x0005b;42&#x0005d;</xref>. Fluorochromes utilized were Alexa 488 and Alexa 594. At least 100 cells were analyzed per experimental point <xref ref-type="bibr" rid="pone.0001372-Buck3">&#x0005b;41&#x0005d;</xref>. We used TO-PRO-3 (Molecular Probes, Eugene, Oregon) to analyze nuclear morphology. The degree of liver fibrosis was determined by using the Mallory's trichrome and the Sirius red Immunohistochemistry <xref ref-type="bibr" rid="pone.0001372-Bedossa1">&#x0005b;18&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Jimenez1">&#x0005b;19&#x0005d;</xref>. The interobserver agreement was &#x0003e;90&#x00025;.</p></sec><sec id="s4e"><title>Liver Fibrosis</title><p>We determined the degree of liver fibrosis in coded samples. We evaluated liver fibrosis employing the following methods: i) microscopic morphology; ii) semi-quantitative METAVIR grading system <xref ref-type="bibr" rid="pone.0001372-Bedossa1">&#x0005b;18&#x0005d;</xref> ; iii) collagen type 1 immunofluorescence ; iv) quantitative Sirius red collagen-binding assay as described <xref ref-type="bibr" rid="pone.0001372-Jimenez1">&#x0005b;19&#x0005d;</xref> ; v) quantitative hydroxyproline collagen content as described <xref ref-type="bibr" rid="pone.0001372-Edwards1">&#x0005b;43&#x0005d;</xref> RT-PCR for collagen type 1; vii) RT-PCR for &#x003b1;-smooth muscle actin (present in activated HSC); and viii) RT-PCR for transforming growth factor-&#x003b2; (a pro-fibrotic cytokine) <xref ref-type="bibr" rid="pone.0001372-Chojkier1">&#x0005b;4&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Friedman1">&#x0005b;7&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Bataller1">&#x0005b;8&#x0005d;</xref>.</p><p>For measuring hydroxyproline, the liver was excised and a portion was removed and weighed. Hydrolysis of 10 mg tissue/1ml of 6 M HCl was performed at 120&#x000b0;C in a pressure vessel for 4 hr. Samples were dried overnight in a vacuum desiccator, diluted to fall into the assay sensitivity range and internal standards were prepared. The chloramine-T reagent was prepared and 1 ml was added to each sample. The samples were incubated for 20 minutes. One ml of aldehyde-perchloric acid reagent was added to each sample and incubated at 60&#x000b0;C for 15 minutes. Samples were cooled and absorbance was read at 550nm for samples and standards. Concentrations were determined from the standard curve.</p></sec><sec id="s4f"><title>RT-PCR Analysis</title><p>We isolated total RNA from control and experimental liver samples using Trizol (Invitrogen). Samples were treated with DNase using Turbo DNA-free (Ambion) and precipitated with chloroform as per manufacturer's protocol. cDNA synthesis was performed using 250 ng of total RNA with the AffinityScript Reverse Transcriptase (Stratagene). Specific sets of primers were utilized for each RT-PCR amplification for collagen &#x003b1;1 type 1, &#x003b1;-SMA and TGF-&#x003b2;, as described by the manufacturer (SuperArray, Frederick, MD).</p></sec><sec id="s4g"><title>Liver Inflammation Genes</title><p>The liver expression of 86 inflammation genes was determined by using the RT<sup>2</sup> Quantitative Real-Time PCR Array as described by the manufacturer (SuperArray, Frederick, MD). Control and experimental liver samples were analyzed together with internal control samples for the RNA purification and amplification steps, as well as for housekeeping genes (&#x003b2; glucuronidase, hypoxanthine guanine phosphoribosyl transferase 1, heat shock protein1&#x003b2;, glyceraldehyde-3-phosphate dehydrogenase, and &#x003b2;-actin), using the BioRad iQ5 real-time PCR detection system (BioRad, Hercules, CA). Isolation of total RNA, treatment with DNase, precipitation with chloroform, and cDNA synthesis was performed using 1 &#x000b5;g of total RNA as described for RT-PCR following the manufacturer's recommendations.</p></sec><sec id="s4h"><title>Cyp-2E1 Expression and Activity</title><p>Cyp-2E1 mRNA was measured by RT-PCR in control and experimental liver samples as described above for RT-PCR. Cyp-2E1 protein in liver samples was detected by western blot, following the chemoluminescence protocol (Perkin-Elmer, Shelton, Connecticut) using purified antibodies against Cyp-2E1 (Santa Cruz Biotechnology) as described below.</p><p>Cyp-2E1 activity was assessed in a cell-free system, using a recombinant Cyp-2E1 and a specific substrate <xref ref-type="bibr" rid="pone.0001372-Marks1">&#x0005b;44&#x0005d;</xref>. Inhibition of Cyp-2E1 activity was achieved using diethyldithiocarbamate (Sigma-Aldrich). We evaluated the effects of the RSK-inhibitory Ac-KAla217VD-CHO peptide (American Peptide) on Cyp-2E1 activity as described per manufacturer (Invitrogen). The standard curve was prepared using dilutions of the fluorescent standard. Master-mix containing the P450 baculosomes reagent, regeneration system, and reaction buffer were added to the designated well of the reaction plate. The plate was incubated for 20 minutes at room temperature to allow the compounds to interact with the Cyp-2E1 in the absence of enzyme turnover. The reaction plate was pre-read at this point to measure any auto-fluorescence. The reaction was initiated with the addition of the reaction mixture containing substrate and NADP. The plate was incubated for 30 minutes, and the fluorescence was measured at 400 and 460 nm. Data analysis was performed as suggested by the manufacturer.</p></sec><sec id="s4i"><title>Immunoprecipitation and Immunoblots</title><p>Pre-cleared stellate cell lysates were incubated for 2 h with purified C/EBP&#x003b2;, RSK, TRADD or caspase 8 antibodies followed by the addition of A/G&#x0002b; agarose (Santa Cruz Biotechnology) for 12 h. The immunoprecipitation reactions each contained 500 &#x000b5;g of total protein and 2 &#x000b5;g antibody (or purified IgG pre-immune serum as negative control). Immunoprecipitates were washed 3 times in 500 ml cell lysis buffer <xref ref-type="bibr" rid="pone.0001372-Descombes1">&#x0005b;45&#x0005d;</xref> and resolved by SDS-PAGE, and C/EBP&#x003b2;, RSK, RSKp380, TNFR-1, TRADD, RIP, TRAF-2, &#x003b2;-actin and caspase 8 detected by western blot <xref ref-type="bibr" rid="pone.0001372-Buck3">&#x0005b;41&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Buck5">&#x0005b;46&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Trautwein1">&#x0005b;47&#x0005d;</xref>, following the chemoluminescence protocol (Perkin-Elmer, Shelton, Connecticut) using purified antibodies against C/EBP&#x003b2; (C-19; aa 258-276), RSK, RSKp380, TRADD, RIP, &#x003b2;-actin (Santa Cruz Biotechnology), procaspase 8 (PharMingen) and C/EBP&#x003b2;-PhosphoThr217 <xref ref-type="bibr" rid="pone.0001372-Buck2">&#x0005b;10&#x0005d;</xref>. Negative samples were performed omitting the first antibody.</p></sec><sec id="s4j"><title>Caspase Activity</title><p>Purified synthetic N-acetyl, C-aldehyde KAVD tetrapeptide (American Peptide Company, Sunnyvale, California) were assayed for their ability to enhance the activity of purified human recombinant caspase 8 (catalogue # 201-041-C005) (Alexis Biochemicals). The sequence of caspase 8 includes S217 through D479 cloned into an expression vector containing a 21 amino acid linker at the N-terminus. Thus, the prodomain (first 220 amino acids) is essentially missing. The fragment is cleaved at D385 and the active caspase 8 is essentially identical to that identified in apoptotic cells <xref ref-type="bibr" rid="pone.0001372-Stennicke1">&#x0005b;48&#x0005d;</xref>. Caspase 8 activity was also measured in stellate cell lysates, using recombinant caspase 8 as a standard for activity. Caspase activity was determined by the release of the <italic>p</italic>-nitroanaline colorimetric (Alexis Biochemicals, San Diego, California) substrate for caspase 8 (catalogue # 260-045) within the linear part of the kinetic assay <xref ref-type="bibr" rid="pone.0001372-Thornberry1">&#x0005b;49&#x0005d;</xref><xref ref-type="bibr" rid="pone.0001372-Stennicke2">&#x0005b;50&#x0005d;</xref>. Active caspase 3 was determined with specific antibodies (PharMingen).</p></sec><sec id="s4k"><title>RSK Activity</title><p>RSK activity was measured by the QTL Lightspeed assay (QTL Biosystems; Santa Fe, New Mexico) using purified recombinant RSK-2 (4,333 U/mg) (Upstate, New York), and staurosporine (0.01 nM) as a control inhibitor. RSK activity was measured in the presence or absence of Ac-KThr217VD-CHO (200 &#x000b5;M), Ac-KAla217VD-CHO (200 &#x000b5;M), or C/EBP&#x003b2;216-253-Ala217 (0.25 nM) peptides.</p></sec><sec id="s4l"><title>Human Livers</title><p>We obtained anonymous, de-identified liver samples from 4 patients with chronic hepatitis C viral infection and severe liver fibrosis (Metavir scores of 3 or 4) (53&#x000b1;17 years) and from 3 control subjects without liver disease (60&#x000b1;13 years) (NDRI). The protocol was approved by the University of California, San Diego Human Protection Program.</p></sec><sec id="s4m"><title>Statistical Analysis</title><p>Results are expressed as mean (&#x000b1;SD). Either the Student-<italic>t</italic> or the Wilcoxon Mann-Whitney tests were used to evaluate the differences of the means between groups for parametric and non-parametric populations, respectively, with a <italic>P</italic> value of &#x0003c;0.05 as significant.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0001372.s001"><label>Table S1</label><caption><p>C/EBP&#x003b2;-Ala217 mice have less liver damage after CCl<sub>4</sub> treatment. Animals received either mineral oil &#x0005b;MO&#x0005d; or CCl<sub>4</sub>. Thirty hours after a single intraperitoneal dose of CCl<sub>4</sub> C/EBP&#x003b2;&#x0002b;/&#x0002b; (n: 9) and C/EBP&#x003b2;&#x02212;/&#x02212; (n: 9) mice had higher serum alanine aminotransferase (ALT) levels than C/EBP&#x003b2;- Ala217 mice (n: 9) (P&#x0003c;0.005 ). Results are representative of three independent experiments.</p><p>(0.02 MB DOC)</p></caption><media xlink:href="pone.0001372.s001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0001372.s002"><label>Figure S1</label><caption><p>Transgenic C/EBP&#x003b2;-Ala217 and C/EBP&#x003b2;&#x0002b;/&#x0002b; mice have similar Cyp-2E1 expression in the liver. Mice were treated with CCl<sub>4</sub> or control mineral oil for 24 or 72 hr as described in <xref ref-type="sec" rid="s4">Materials and methods</xref>. A. Liver Cyp-2E1 RNA as determined by RT-PCR was comparable at baseline and after CCl<sub>4</sub> treatment in C/EBP&#x003b2; &#x0002b;/&#x0002b; &#x0005b;wt&#x0005d; and C/EBP&#x003b2;-Ala217 mice (NS). B. Liver Cyp-2E1 protein as determined by western blot was comparable at baseline and after CCl<sub>4</sub>, treatment in C/EBP&#x003b2; &#x0002b;/&#x0002b; &#x0005b;wt&#x0005d; and C/EBP&#x003b2;- Ala217 mice (NS). C. Cyp-2E1 activity as determined in a cell free system using a recombinant Cyp-2E1 protein was comparable in the absence or presence of the RSK-inhibitory Ac-KAVD-CHO peptide (1-1000 ng/ml). Values are expressed as percentage of control Cyp-2E1 activity (open bars) (NS). A specific Cyp-2E1 inhibitor was used as a positive control (closed bar).</p><p>(0.66 MB TIF)</p></caption><media xlink:href="pone.0001372.s002.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0001372.s003"><label>Figure S2</label><caption><p>The association of C/EBP&#x003b2; with active caspase 8, TNFR1, TRAF2, TRADD and RIP is induced by inhibiting RSK in HSC. A Reciprocal TRADD immunoprecipitation of experiment described in (7A) confirmed the association of unphosphorylated C/EBP&#x003b2; with active caspase 8. &#x003b2; - Actin was used as an internal control for the immunoprecipitations. B. Reciprocal TNFR1 immunoprecipitation of experiment described in (<xref ref-type="fig" rid="pone-0001372-g007">Fig. 7B</xref>) confirmed the association of unphosphorylated C/EBP&#x003b2; with TNFR1. &#x003b2;- Actin was used as an internal control for the immunoprecipitations. C. Reciprocal TRAF2 immunoprecipitation of experiment described in (<xref ref-type="fig" rid="pone-0001372-g007">Fig. 7C</xref>) confirmed the association of unphosphorylated C/EBP&#x003b2; with TRAF2. &#x003b2;- Actin was used as an internal control for the immunoprecipitations.</p><p>(0.56 MB TIF)</p></caption><media xlink:href="pone.0001372.s003.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0001372.s004"><label>Figure S3</label><caption><p>Primary mouse hepatocytes are refractory to the induction of apoptosis by the RSK-inhibitory Ac-KAVD-CHO peptide. Primary mouse hepatocytes were isolated from C/EBP &#x003b2; &#x0002b;/&#x0002b; &#x0005b;wt&#x0005d; mice as described in <xref ref-type="sec" rid="s4">Materials and methods</xref>. Cells were treated with Ac-KAVD-CHO peptide for 18 hr. Apoptosis was measured by the annexin-V binding assay as described in <xref ref-type="sec" rid="s4">Materials and methods</xref>. The peptide did not induce hepatocyte apoptosis when compared to control hepatocytes (NS).</p><p>(0.18 MB TIF)</p></caption><media xlink:href="pone.0001372.s004.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0001372.s005"><label>Figure S4</label><caption><p>The RSK-inhibitory peptide blocks liver fibrosis induced by CCl<sub>4</sub>. Mice were from the experiment described in (<xref ref-type="fig" rid="pone-0001372-g008">Fig 8E and F</xref>). Representative Sirius red immunohistochemistry for collagen (in red; arrowhead). Marked increase in liver collagen in a cirrhotic pattern was observed in C/EBP&#x003b2; &#x0002b;/&#x0002b; treated with CCl<sub>4</sub> but not in animals receiving the RSK-inbitory peptide.</p><p>(0.18 MB TIF)</p></caption><media xlink:href="pone.0001372.s005.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank J Blenis for the RSK expression vectors, Daniela Traykova, Melissa Mitrou, Antimone Dewing, and Janel Suburu for technical assistance and Marcus Kouma for the preparation of the figures.</p></ack><ref-list><title>References</title><ref id="pone.0001372-1"><label>1</label><citation citation-type="book"><article-title>Reducing Risks, Promoting Healthy Life.</article-title><source>Reducing Risks, Promoting Healthy Life 2002</source><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><fpage>1</fpage><lpage>230</lpage></citation></ref><ref id="pone.0001372-2"><label>2</label><citation citation-type="book"><year>5491</year><article-title>Report 04-5491. Executive Summary.</article-title><source>Action Plan for Liver Disease Research</source><publisher-name>U.S. Department of Health and Human Services: (2004) NIH</publisher-name><fpage>1</fpage><lpage>6</lpage></citation></ref><ref id="pone.0001372-Chung1"><label>3</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>R</given-names></name><name><surname>Podolsky</surname><given-names>D</given-names></name></person-group><year>2005</year><article-title>Cirrhosis and its Complications.</article-title><source>Harrison's Principles of Internal Medicine</source><publisher-loc>New York</publisher-loc><publisher-name>McGraw-Hill</publisher-name><fpage>1754</fpage><lpage>1767</lpage></citation></ref><ref id="pone.0001372-Chojkier1"><label>4</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Chojkier</surname><given-names>M</given-names></name></person-group><year>1998</year><article-title>Regulation of collagen gene expression.</article-title><person-group person-group-type="editor"><name><surname>Strain</surname><given-names>A</given-names></name><name><surname>Diehl</surname><given-names>A</given-names></name></person-group><source>Liver growth and repair</source><publisher-loc>London</publisher-loc><publisher-name>Chapman &#x00026; Hall</publisher-name><fpage>430</fpage><lpage>450</lpage></citation></ref><ref id="pone.0001372-Buck1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>M</given-names></name><name><surname>Poli</surname><given-names>V</given-names></name><name><surname>van der Geer</surname><given-names>P</given-names></name><name><surname>Chojkier</surname><given-names>M</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name></person-group><year>1999</year><article-title>Phosphorylation of rat serine 105 or mouse threonine 217 in C/EBPb is required for hepatocyte proliferation induced by TGFa.</article-title><source>Mol Cell</source><volume>4</volume><fpage>1087</fpage><lpage>1092</lpage><pub-id pub-id-type="pmid">10635333</pub-id></citation></ref><ref id="pone.0001372-Lee1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Buck</surname><given-names>M</given-names></name><name><surname>Houglum</surname><given-names>K</given-names></name><name><surname>Chojkier</surname><given-names>M</given-names></name></person-group><year>1995</year><article-title>Activation of hepatic stellate cells by TGFa and collagen type I is mediated by oxidative stress through c-myb expression.</article-title><source>J Clin Invest</source><volume>96</volume><fpage>2461</fpage><lpage>2468</lpage><pub-id pub-id-type="pmid">7593635</pub-id></citation></ref><ref id="pone.0001372-Friedman1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>SL</given-names></name></person-group><year>2000</year><article-title>Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury.</article-title><source>J Biol Chem</source><volume>275</volume><fpage>2247</fpage><lpage>2250</lpage><pub-id pub-id-type="pmid">10644669</pub-id></citation></ref><ref id="pone.0001372-Bataller1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bataller</surname><given-names>R</given-names></name><name><surname>Brenner</surname><given-names>DA</given-names></name></person-group><year>2005</year><article-title>Liver Fibrosis.</article-title><source>J Clin Invest</source><volume>115</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">15690074</pub-id></citation></ref><ref id="pone.0001372-AnkomaSey1"><label>9</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ankoma-Sey</surname><given-names>V</given-names></name><name><surname>Friedman</surname><given-names>S</given-names></name></person-group><year>1998</year><article-title>Hepatic stellate cells.</article-title><person-group person-group-type="editor"><name><surname>Strain</surname><given-names>A</given-names></name><name><surname>Diehl</surname><given-names>A</given-names></name></person-group><source>Liver growth and repair</source><publisher-loc>London</publisher-loc><publisher-name>Chapman &#x00026; Hall</publisher-name><fpage>512</fpage><lpage>537</lpage></citation></ref><ref id="pone.0001372-Buck2"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>M</given-names></name><name><surname>Poli</surname><given-names>V</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Chojkier</surname><given-names>M</given-names></name></person-group><year>2001</year><article-title>C/EBPb phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival.</article-title><source>Mol Cell</source><volume>8</volume><fpage>807</fpage><lpage>816</lpage><pub-id pub-id-type="pmid">11684016</pub-id></citation></ref><ref id="pone.0001372-Bonni1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonni</surname><given-names>A</given-names></name><name><surname>Brunet</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>A</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Takasu</surname><given-names>M</given-names></name><etal/></person-group><year>1999</year><article-title>Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.</article-title><source>Science</source><volume>286</volume><fpage>1358</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">10558990</pub-id></citation></ref><ref id="pone.0001372-Bhatt1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>R</given-names></name><name><surname>Ferrell</surname><given-names>J</given-names></name></person-group><year>1999</year><article-title>The protein kinase p90 Rsk as an essential mediator of cytostatic factor activity.</article-title><source>Science</source><volume>286</volume><fpage>1362</fpage><lpage>1365</lpage><pub-id pub-id-type="pmid">10558991</pub-id></citation></ref><ref id="pone.0001372-Gross1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>S</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name><name><surname>Lewellyn</surname><given-names>A</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name></person-group><year>1999</year><article-title>Induction of metaphase arrest in cleaving Xenopus embryos by the protein kinase p90<sup>Rsk</sup>.</article-title><source>Science</source><volume>286</volume><fpage>1365</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">10558992</pub-id></citation></ref><ref id="pone.0001372-SassoneCorsi1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sassone-Corsi</surname><given-names>P</given-names></name><name><surname>Mizzen</surname><given-names>C</given-names></name><name><surname>Cheung</surname><given-names>P</given-names></name><name><surname>Crosio</surname><given-names>C</given-names></name><name><surname>Monaco</surname><given-names>L</given-names></name><etal/></person-group><year>1999</year><article-title>Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3.</article-title><source>Science</source><volume>285</volume><fpage>886</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">10436156</pub-id></citation></ref><ref id="pone.0001372-Nakajima1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Fukamizu</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>J</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Fisher</surname><given-names>T</given-names></name><etal/></person-group><year>1996</year><article-title>The signal-dependent coactivator CBP is a nuclear target for pp90RSK.</article-title><source>Cell</source><volume>86</volume><fpage>465</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">8756728</pub-id></citation></ref><ref id="pone.0001372-Rudolph1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Millard</surname><given-names>M</given-names></name><name><surname>Schreiber-Agus</surname><given-names>N</given-names></name><name><surname>DePinho</surname><given-names>R</given-names></name></person-group><year>2000</year><article-title>Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery.</article-title><source>Science</source><volume>287</volume><fpage>1253</fpage><lpage>1258</lpage><pub-id pub-id-type="pmid">10678830</pub-id></citation></ref><ref id="pone.0001372-Constandinou1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Constandinou</surname><given-names>C</given-names></name><name><surname>Henderson</surname><given-names>N</given-names></name><name><surname>Iredale</surname><given-names>J</given-names></name></person-group><year>2005</year><article-title>Modeling liver fibrosis in rodents.</article-title><source>Methods Mol Med</source><volume>117</volume><fpage>237</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">16118456</pub-id></citation></ref><ref id="pone.0001372-Bedossa1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bedossa</surname><given-names>P</given-names></name><name><surname>Poynard</surname><given-names>T</given-names></name></person-group><year>1994</year><article-title>Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C.</article-title><source>Hepatology</source><volume>20</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">8020885</pub-id></citation></ref><ref id="pone.0001372-Jimenez1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>W</given-names></name><name><surname>Pares</surname><given-names>A</given-names></name><name><surname>Caballeria</surname><given-names>J</given-names></name><name><surname>Heredia</surname><given-names>D</given-names></name><name><surname>Brugera</surname><given-names>M</given-names></name><etal/></person-group><year>1985</year><article-title>Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric method.</article-title><source>Hepatology</source><volume>5</volume><fpage>815</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">4029893</pub-id></citation></ref><ref id="pone.0001372-Chojkier2"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chojkier</surname><given-names>M</given-names></name><name><surname>Fierer</surname><given-names>J</given-names></name></person-group><year>1985</year><article-title>D-Galactosamine hepatotoxicity is associated with endotoxin-sensitivity and mediated by lymphoreticular cells in mice.</article-title><source>Gastroenterology</source><volume>88</volume><fpage>115</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">3880554</pub-id></citation></ref><ref id="pone.0001372-Friedman2"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>SL</given-names></name><name><surname>Arthur</surname><given-names>MJ</given-names></name></person-group><year>1989</year><article-title>Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium.</article-title><source>J Clin Invest</source><volume>84</volume><fpage>1780</fpage><lpage>1785</lpage><pub-id pub-id-type="pmid">2556445</pub-id></citation></ref><ref id="pone.0001372-Matsuoka1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>M</given-names></name><name><surname>Tsukamoto</surname><given-names>H</given-names></name></person-group><year>1990</year><article-title>Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor b: implication for a pathogenetic role in alcoholic liver fibrogenesis.</article-title><source>Hepatology</source><volume>11</volume><fpage>599</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">2328954</pub-id></citation></ref><ref id="pone.0001372-Passino1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Passino</surname><given-names>MA</given-names></name><name><surname>Adams</surname><given-names>RA</given-names></name><name><surname>Sikorski</surname><given-names>SL</given-names></name><name><surname>Akassoglou</surname><given-names>K</given-names></name></person-group><year>2007</year><article-title>Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR.</article-title><source>Science</source><volume>315</volume><fpage>1853</fpage><lpage>1856</lpage><pub-id pub-id-type="pmid">17395831</pub-id></citation></ref><ref id="pone.0001372-LeCouter1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeCouter</surname><given-names>J</given-names></name><name><surname>Moritz</surname><given-names>DR</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Phillips</surname><given-names>GL</given-names></name><name><surname>Liang</surname><given-names>XH</given-names></name><etal/></person-group><year>2003</year><article-title>Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.</article-title><source>Science</source><volume>299</volume><fpage>890</fpage><lpage>893</lpage><pub-id pub-id-type="pmid">12574630</pub-id></citation></ref><ref id="pone.0001372-Chojkier3"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chojkier</surname><given-names>M</given-names></name></person-group><year>2003</year><article-title>Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids.</article-title><source>J Hepatol</source><volume>39</volume><fpage>437</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">12927933</pub-id></citation></ref><ref id="pone.0001372-Chojkier4"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chojkier</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>Troglitazone and liver injury: in search of answers.</article-title><source>Hepatology</source><volume>41</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">15657914</pub-id></citation></ref><ref id="pone.0001372-Koop1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koop</surname><given-names>DR</given-names></name></person-group><year>1992</year><article-title>Oxidative and reductive metabolism by cytochrome P450 2E1.</article-title><source>FASEB J</source><volume>6</volume><fpage>724</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">1537462</pub-id></citation></ref><ref id="pone.0001372-Bravo1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bravo</surname><given-names>R</given-names></name><name><surname>Frank</surname><given-names>R</given-names></name><name><surname>Blundell</surname><given-names>PA</given-names></name><name><surname>MacDonald-Bravo</surname><given-names>H</given-names></name></person-group><year>1987</year><article-title>Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.</article-title><source>Nature</source><volume>326</volume><fpage>515</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">2882423</pub-id></citation></ref><ref id="pone.0001372-Micheau1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Micheau</surname><given-names>O</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><year>2003</year><article-title>Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes.</article-title><source>Cell</source><volume>114</volume><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">12887920</pub-id></citation></ref><ref id="pone.0001372-Leite1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>F</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><name><surname>Sylte</surname><given-names>MJ</given-names></name><name><surname>Page</surname><given-names>T</given-names></name><name><surname>Atapattu</surname><given-names>D</given-names></name><etal/></person-group><year>2002</year><article-title>Inflammatory Cytokines Enhance the Interaction of Mannheimia haemolytica Leukotoxin with Bovine Peripheral Blood Neutrophils In Vitro.</article-title><source>Infect Immun</source><volume>70</volume><fpage>4336</fpage><lpage>4343</lpage><pub-id pub-id-type="pmid">12117943</pub-id></citation></ref><ref id="pone.0001372-Zhang1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>HZ</given-names></name><name><surname>Kasibhatia</surname><given-names>S</given-names></name><name><surname>Guastella</surname><given-names>J</given-names></name><name><surname>Tseng</surname><given-names>B</given-names></name><name><surname>Drewe</surname><given-names>J</given-names></name><etal/></person-group><year>2003</year><article-title>N-Ac-DEVD-N'-(Polyfluorobenozoyl)-R110: novel cell-permeable fluorogenic caspase substrates for the detection of caspase activity and apoptosis.</article-title><source>Bioconjug Chem</source><volume>14</volume><fpage>458</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">12643757</pub-id></citation></ref><ref id="pone.0001372-Spierings1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spierings</surname><given-names>D</given-names></name><name><surname>McStay</surname><given-names>G</given-names></name><name><surname>Saleh</surname><given-names>M</given-names></name><name><surname>Bender</surname><given-names>C</given-names></name><name><surname>Chipuk</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis.</article-title><source>Science</source><volume>310</volume><fpage>66</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">16210526</pub-id></citation></ref><ref id="pone.0001372-Iredale1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iredale</surname><given-names>J</given-names></name></person-group><year>2001</year><article-title>Stellate cell behavior during resolution of liver injury.</article-title><source>Semin Liv Dis</source><volume>21</volume><fpage>427</fpage><lpage>436</lpage></citation></ref><ref id="pone.0001372-Friedman3"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>SL</given-names></name><name><surname>Bansal</surname><given-names>MB</given-names></name></person-group><year>2006</year><article-title>Reversal of hepatic fibrosis&#x02013;fact or fantasy?</article-title><source>Hepatology</source><volume>43</volume><fpage>S82</fpage><lpage>S88</lpage><pub-id pub-id-type="pmid">16447275</pub-id></citation></ref><ref id="pone.0001372-Menard1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menard</surname><given-names>C</given-names></name><name><surname>Hein</surname><given-names>P</given-names></name><name><surname>Paquin</surname><given-names>A</given-names></name><name><surname>Savelson</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>XM</given-names></name><etal/></person-group><year>2002</year><article-title>An essential role for a MEK-C/EBP pathway during growth factor-regulated cortical neurogenesis.</article-title><source>Neuron</source><volume>36</volume><fpage>597</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">12441050</pub-id></citation></ref><ref id="pone.0001372-Tanaka1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Umemoro</surname><given-names>M</given-names></name><name><surname>Yoneda</surname><given-names>Y</given-names></name><etal/></person-group><year>1995</year><article-title>Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages.</article-title><source>Cell</source><volume>80</volume><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">7530603</pub-id></citation></ref><ref id="pone.0001372-Yoon1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Ewing</surname><given-names>SJ</given-names></name><name><surname>Smart</surname><given-names>RC</given-names></name></person-group><year>2006</year><article-title>Decreased survival of C/EBP&#x0005b;beta&#x0005d;-deficient keratinocytes is due to aberrant regulation of p53 levels and function.</article-title><source>Oncogene</source><volume>26</volume><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">16832342</pub-id></citation></ref><ref id="pone.0001372-Ranjan1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ranjan</surname><given-names>P</given-names></name><name><surname>Boss</surname><given-names>J</given-names></name></person-group><year>2006</year><article-title>C/EBb regulates TNF induced MnSOD expression and protection against apoptosis.</article-title><source>Apoptosis</source><volume>11</volume><fpage>1837</fpage><lpage>1849</lpage><pub-id pub-id-type="pmid">16850160</pub-id></citation></ref><ref id="pone.0001372-3"><label>39</label><citation citation-type="book"><article-title>Report 04-5491. Liver Cancer.</article-title><source>Action Plan for Liver Disease Research. (2004)U.S. Department of Health and Human Services: NIH</source><fpage>137</fpage><lpage>143</lpage></citation></ref><ref id="pone.0001372-Screpanti1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Screpanti</surname><given-names>I</given-names></name><name><surname>Romani</surname><given-names>L</given-names></name><name><surname>Musiani</surname><given-names>P</given-names></name><name><surname>Modesti</surname><given-names>A</given-names></name><name><surname>Fattori</surname><given-names>E</given-names></name><etal/></person-group><year>1995</year><article-title>Lymphoproliferative disorder and imbalanced T-helper response in C/EBPb-deficient mice.</article-title><source>EMBO J</source><volume>14</volume><fpage>1932</fpage><lpage>1941</lpage><pub-id pub-id-type="pmid">7744000</pub-id></citation></ref><ref id="pone.0001372-Buck3"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>M</given-names></name><name><surname>Turler</surname><given-names>H</given-names></name><name><surname>Chojkier</surname><given-names>M</given-names></name></person-group><year>1994</year><article-title>LAP (NF-IL6), a tissue-specific transcriptional activator, is an inhibitor of hepatoma cell proliferation.</article-title><source>EMBO J</source><volume>13</volume><fpage>851</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">7906646</pub-id></citation></ref><ref id="pone.0001372-Buck4"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Chojkier</surname><given-names>M</given-names></name></person-group><year>2001</year><article-title>Nuclear export of phosphorylated C/EBPb mediates the inhibition of albumin expression by TNFa.</article-title><source>EMBO J</source><volume>20</volume><fpage>6712</fpage><lpage>6723</lpage><pub-id pub-id-type="pmid">11726507</pub-id></citation></ref><ref id="pone.0001372-Edwards1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>CA</given-names></name><name><surname>O'Brien</surname><given-names>WD</given-names><suffix>Jr</suffix></name></person-group><year>1980</year><article-title>Modified assay for determination of hydroxyproline in a tissue hydrolyzate.</article-title><source>Clin Chim Acta</source><volume>104</volume><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">7389130</pub-id></citation></ref><ref id="pone.0001372-Marks1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>BD</given-names></name><name><surname>Smith</surname><given-names>RW</given-names></name><name><surname>Braun</surname><given-names>HA</given-names></name><name><surname>Goossens</surname><given-names>TA</given-names></name><name><surname>Christenson</surname><given-names>M</given-names></name><etal/></person-group><year>2002</year><article-title>A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate.</article-title><source>Assay Drug Dev Technol</source><volume>1</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">15090158</pub-id></citation></ref><ref id="pone.0001372-Descombes1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Descombes</surname><given-names>P</given-names></name><name><surname>Chojkier</surname><given-names>M</given-names></name><name><surname>Lichtsteiner</surname><given-names>S</given-names></name><name><surname>Falvey</surname><given-names>E</given-names></name><name><surname>Schibler</surname><given-names>U</given-names></name></person-group><year>1990</year><article-title>LAP, a novel member of the C/EBP gene family, encodes a liver-enriched transcriptional activator protein.</article-title><source>Genes Dev</source><volume>4</volume><fpage>1541</fpage><lpage>1551</lpage><pub-id pub-id-type="pmid">2253878</pub-id></citation></ref><ref id="pone.0001372-Buck5"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>M</given-names></name><name><surname>Chojkier</surname><given-names>M</given-names></name></person-group><year>1996</year><article-title>Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants.</article-title><source>EMBO J</source><volume>15</volume><fpage>1753</fpage><lpage>1765</lpage><pub-id pub-id-type="pmid">8617220</pub-id></citation></ref><ref id="pone.0001372-Trautwein1"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trautwein</surname><given-names>C</given-names></name><name><surname>Caelles</surname><given-names>C</given-names></name><name><surname>van der Geer</surname><given-names>P</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name><etal/></person-group><year>1993</year><article-title>Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain.</article-title><source>Nature</source><volume>364</volume><fpage>544</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">8336793</pub-id></citation></ref><ref id="pone.0001372-Stennicke1"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stennicke</surname><given-names>HR</given-names></name><name><surname>Salvesen</surname><given-names>GS</given-names></name></person-group><year>1997</year><article-title>Biochemical characteristics of caspases -3, -6, -7, and -8.</article-title><source>J Biol Chem</source><volume>272</volume><fpage>25719</fpage><lpage>25723</lpage><pub-id pub-id-type="pmid">9325297</pub-id></citation></ref><ref id="pone.0001372-Thornberry1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thornberry</surname><given-names>N</given-names></name><name><surname>Bull</surname><given-names>H</given-names></name><name><surname>Calaycay</surname><given-names>J</given-names></name><name><surname>Chapman</surname><given-names>KT</given-names></name><name><surname>Howard</surname><given-names>AD</given-names></name><etal/></person-group><year>1992</year><article-title>A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.</article-title><source>Nature</source><volume>356</volume><fpage>768</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">1574116</pub-id></citation></ref><ref id="pone.0001372-Stennicke2"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stennicke</surname><given-names>HR</given-names></name><name><surname>Salvesen</surname><given-names>GS</given-names></name></person-group><year>2000</year><article-title>Caspase assays.</article-title><source>Meth Enzymol</source><volume>322</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">10914007</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>Grants from the NIDDK, NCI, and the Department of Veterans Affairs</p></fn></fn-group></back></article> 